H. PYLORI · COMPLETE REFERENCE · WELYON
It is a systemic infection — carried by approximately one in three Americans — associated in the peer-reviewed literature with eight conditions that are routinely managed in isolation, by different specialists, without the upstream infection on their differential.
This page documents what H. pylori is, how it causes harm, what the evidence shows across those eight conditions, how to test for it, and why it consistently goes uninvestigated. It is maintained by Welyon as part of its educational mission and is updated as evidence develops.
The question is not whether H. pylori causes ulcers and gastric cancer. The question is whether a chronic infection carried by roughly one-third of Americans is being overlooked in patients whose symptoms appear outside gastroenterology.
H. pylori is usually classified as a gastroenterology problem. The evidence suggests it is something more: a common chronic infection — carried by roughly one in three Americans — with documented associations across eight systemic conditions that are routinely managed by specialists who do not test for H. pylori because their workflows were not designed around it.
Those eight conditions are iron deficiency anemia, immune thrombocytopenia, chronic spontaneous urticaria, thyroid autoimmunity, unexplained fatigue, vitamin B12 deficiency, cognitive impairment, and metabolic syndrome. The evidence for some of these associations is strong — randomized trials for iron deficiency, guideline support for testing in ITP. For others, such as chronic urticaria (nine randomized trials), it is moderate. The testing infrastructure exists. The gap is not scientific.
The gap is structural: a consequence of medicine organized by organ system and specialty rather than by upstream cause. A hematologist managing iron deficiency anemia, a dermatologist treating chronic hives, an endocrinologist managing Hashimoto's thyroiditis — none of these specialists has H. pylori in their diagnostic workflow for these conditions, even when the peer-reviewed evidence supports investigation.
This page documents the evidence, explains the mechanisms, and describes why the connection is consistently missed. It is not an argument that H. pylori explains every chronic symptom. It is an examination of where the evidence supports testing for a common chronic infection outside traditional gastroenterology workflows — and why that testing is not happening.
Key Takeaways
When a patient presents to a hematologist with iron deficiency anemia, the hematologist investigates blood loss, nutritional deficiency, and malabsorption disorders — the causes within their specialty's framework. When a patient presents to a dermatologist with chronic hives, the dermatologist investigates allergens, autoimmune triggers, and physical causes. When a patient presents to an endocrinologist with Hashimoto's thyroiditis, the endocrinologist investigates thyroid function, antibody levels, and genetic predisposition. None of these specialists, working within their guidelines, is looking for a gastric infection. Not because the evidence doesn't exist. Because the guidelines weren't built around it.
This is the diagnostic gap. It is not a gap in knowledge — the peer-reviewed literature documenting H. pylori's associations with these conditions spans decades and includes randomized controlled trials, meta-analyses, and in one case a 2024 Mendelian randomization study providing genetic causal evidence. It is a gap in workflow: the clinical algorithms that determine which tests get ordered when a patient presents with a given condition were designed around organ systems and specialty boundaries, not upstream infectious causes. H. pylori — a gastric bacterium — falls outside the diagnostic framework of most specialists likely to encounter its downstream consequences — and even where guideline endorsement exists, as it does for ITP, real-world compliance remains at 29%.
The practical consequence is measurable. Hematology guidelines support H. pylori testing in immune thrombocytopenic purpura — a condition in which roughly half of H. pylori-positive patients achieve platelet recovery after eradication alone. Despite this, a 2021 international survey of 186 hematologists across 39 countries found that only 29% always test. The guideline exists. The evidence is strong. The test is inexpensive and non-invasive. The question still isn't being asked in the majority of cases.
Japan offers the most instructive contrast. Since 2013, Japan's national health insurance covers H. pylori testing and treatment for all patients diagnosed with chronic gastritis — not just those with ulcers or cancer symptoms. The result has been a measurable decline in gastric cancer incidence. Japan asked the question systematically. The US equivalent of that systematic approach is not a government program. It is education at the patient level: giving individuals the information to ask a question that their specialist may not be asking for them. That is what this page is for.
The evidence that follows is graded honestly. The associations with iron deficiency anemia and immune thrombocytopenia have strong interventional evidence from randomized controlled trials. Chronic urticaria, thyroid autoimmunity, and B12 deficiency have moderate evidence with documented mechanisms — urticaria the best-supported of them, with nine RCTs. The associations with fatigue and cognitive symptoms have consistent observational evidence that requires further interventional study, and metabolic syndrome is graded exploratory — a consistent association but an unestablished causal direction. Not all eight conditions are equally supported — the evidence hierarchy above makes that explicit. What is consistent across all eight is the same underlying problem: H. pylori is not being investigated in the patients most likely to benefit from investigation.
Helicobacter pylori (H. pylori) is a bacterium that colonizes the stomach lining, carried by approximately one in three Americans and 44% of the global population. The WHO classifies it as a Group 1 carcinogen. Most people who carry it have no GI symptoms — yet the peer-reviewed literature links it to eight systemic conditions routinely managed without the infection on the differential.
This reference is not an argument that H. pylori explains every chronic symptom. It is an examination of where evidence supports testing for a common chronic infection outside traditional gastroenterology workflows.
Evidence grading follows Welyon's three-tier rubric, applied identically across all conditions. Full methodology in §2.7.
The seven subsections below establish what H. pylori is biologically, how it was discovered, how common it is globally and in the United States, how it is acquired and why it never clears on its own, why most carriers have no obvious symptoms, and how strain variation changes the downstream risk picture.
Helicobacter pylori is a gram-negative, flagellated bacterium that colonizes the gastric mucosa — the protective lining of the stomach. It is approximately 3 micrometres long with a diameter of 0.5 micrometres. Its helical shape is not incidental — it evolved specifically to penetrate the viscous mucus layer of the stomach, driven by rotating flagella that allow directed movement toward the less acidic mucosa where colonization occurs (Tegtmeyer N, Wessler S, Backert S. FEBS J. 2011;278(8):1190–1202).[1]
The bacterium has an unusual metabolic requirement — it is microaerophilic, meaning it needs oxygen but at lower concentrations than the atmosphere. It generates energy in part by oxidizing molecular hydrogen produced by intestinal bacteria. This makes it difficult to culture and contributed to decades of delay in recognizing it as the cause of ulcers.
H. pylori possesses one of medicine's more sophisticated persistence mechanisms. When threatened by antibiotics or hostile conditions, it can convert from its active helical form to a dormant coccoid form — a state known as viable but non-culturable (VBNC) — in which standard antibiotics cannot reach it and standard tests may not detect it (Ierardi E, et al. Antibiotics. 2020;9(6):293).[2] It can also form biofilms — structured protective matrices on the gastric mucosa that dramatically reduce antibiotic penetration and contribute to treatment failure (Coticchia JM, et al. J Gastrointest Surg. 2006;10(6):883–889).[3]
The World Health Organization classifies H. pylori as a Group 1 carcinogen — the highest classification, reserved for agents with sufficient evidence of carcinogenicity in humans. It is responsible for an estimated 89% of non-cardia gastric cancers and is linked to roughly 5–6% of all cancers worldwide. Gastric cancer lifetime risk in H. pylori-positive individuals is approximately 1–3% compared to 0.13% in uninfected individuals — a 10–20× relative risk increase. H. pylori is the only bacterium currently known to cause cancer in humans.[4][5][6]
The formal description of H. pylori as the causative agent of gastric ulcers was published by Barry Marshall and Robin Warren in 1983, in The Lancet. They were awarded the Nobel Prize in Physiology or Medicine in 2005.
The discovery of H. pylori is often presented as beginning with Marshall and Warren in the early 1980s. The actual history is older — and instructive.
Robin Warren first observed unusual spiral bacteria in gastric biopsy specimens in 1979. Earlier reports of bacteria associated with gastric conditions had appeared in the late 19th and early 20th century literature, but none gained traction against the prevailing model, which attributed ulcers to stress, diet, and acid excess. The idea that bacteria could survive in the acid environment of the stomach was widely dismissed as implausible.
The most striking pre-Marshall precedent belongs to John Lykoudis — a Greek general practitioner who, in 1958, treated himself for peptic ulcer disease with antibiotics, found it effective, and then began treating patients. Through empirical trial and error he arrived at a combination he patented in 1961 — two quinoline antibiotics, streptomycin, and vitamin A. He is estimated to have treated more than 30,000 patients. He submitted his findings to the Greek medical establishment, was fined by the Athens Medical Association for unorthodox treatment, was rejected by JAMA, and died in 1980 — three years before Marshall and Warren's landmark publication — without recognition (Rigas B, Feretis C, Papavassiliou ED. The Lancet. 1999;354(9190):1634–1635).[7]
What makes this more than historical curiosity: the quinoline class of compounds Lykoudis empirically selected has since demonstrated documented anti-H. pylori activity in modern laboratory research, including activity against biofilm-forming and antibiotic-resistant strains. He arrived at a mechanistically sound approach decades before the mechanism was understood.
This history is not merely interesting. It is a direct precedent for the pattern that recurs throughout H. pylori research: evidence arrives, practice doesn't change. The structural dynamics that produced that delay — specialty silos, paradigm inertia, the difficulty of dislodging an established clinical model — are the same dynamics that today keep H. pylori off the differential for the eight conditions documented in Section III.
H. pylori colonizes approximately 4.4 billion people globally.[8] In the United States, the commonly cited figure is approximately one in three Americans — a 30–40% prevalence. This figure is real but deserves honest context.
There is no annual national census of H. pylori infection. Prevalence estimates derive from a mix of sources: NHANES survey data, regional studies, health-system datasets, and serology studies. Each has limitations. The most important limitation is the distinction between antibody positivity and active infection — these are not the same thing. The IgG antibody test remains positive after successful eradication for months to years. Studies that rely on serology to estimate prevalence may therefore overstate the current rate of active infection.
A second important factor is the cohort effect. H. pylori is acquired primarily in childhood. Americans born in the 1980s–2000s grew up in conditions of higher sanitation, smaller household size, and lower childhood exposure than prior generations. As older generations age out and are replaced by younger generations with lower acquisition rates, overall prevalence is expected to decline — as it has in Japan, South Korea, Western Europe, Australia, and Canada.
The best current estimate for active H. pylori infection among US adults in 2026 is approximately 25–35%, with 30% as a reasonable midpoint. Prevalence is not uniformly distributed. Higher rates occur in lower-income households, overcrowded living conditions, and certain minority populations. A significant additional factor sustaining US prevalence is immigration: large populations from Latin America, Africa, South Asia, and East Asia — where prevalence routinely exceeds 50–70% — meaningfully affect national figures.
The global picture is substantially more severe than the US picture suggests. Overall global prevalence is approximately 44%, but this average obscures dramatic regional variation.[8]
High-burden regions include sub-Saharan Africa (70–90% in many countries), Latin America (50–70%), South and Southeast Asia (50–70%), East Asia including China, South Korea, and Japan (historically 50–70%+), and Eastern Europe (50–70%). In these regions H. pylori infection is the norm rather than the exception — the majority of adults carry it, most from childhood, and most without awareness. Lower-burden regions include Northern and Western Europe (20–40%, declining), Australia and Canada (20–35%), and the United States (25–35%).
Japan as a policy case study. Japan presents one of the most instructive examples of what happens when H. pylori is investigated and addressed systematically at a national level. Since 2013, Japan's national health insurance covers H. pylori testing and treatment for all patients diagnosed with chronic gastritis — not just those with ulcers or cancer symptoms. Gastric cancer incidence in Japan has been declining measurably since the eradication program was scaled. The country with the highest historical gastric cancer rates in the developed world is demonstrating that systematic investigation and treatment changes outcomes at the population level.
The contrast with US practice is direct. In the United States, H. pylori testing is not routine in the absence of GI symptoms. Patients with downstream conditions associated with H. pylori — iron deficiency, thyroid autoimmunity, chronic hives, ITP — are managed by specialists whose diagnostic framework does not include H. pylori.
H. pylori is acquired primarily in childhood through contaminated water, fecal-oral transmission, and close household contact. In low-sanitation environments, waterborne transmission is the dominant route. Once established, it is extraordinarily persistent.
The human immune system does not spontaneously clear H. pylori. The bacterium has evolved specific mechanisms to evade immune clearance: it modulates the local immune response to suppress rather than eliminate the infection, uses its urease enzyme to create an acid-neutralizing microenvironment, and shifts to dormant coccoid form when threatened. A person colonized in childhood who is never treated will carry the infection throughout their adult life. There is no documented case of spontaneous clearance in the peer-reviewed literature.
This persistence is what makes the downstream consequences cumulative. An infection that has been present for decades has had decades to generate systemic inflammation, damage gastric epithelium, impair iron and B12 absorption, and trigger autoimmune cross-reactivity. The longer the infection is present and untreated, the more opportunity it has to advance through Correa's Cascade (Section II) and the more time downstream conditions have to become established.
The standard clinical framing of H. pylori is that most infected people are asymptomatic. This statement is technically accurate in a narrow sense. Most infected people do not develop the conditions currently recognized as classic H. pylori disease: peptic ulcers, gastric cancer, MALT lymphoma. By that definition, they are asymptomatic.
But this framing contains a significant epistemological problem. H. pylori research has historically enrolled patients who presented to gastroenterology clinics with GI complaints. The people who answered "no" to GI symptoms — people with fatigue, iron deficiency, thyroid autoimmunity, or cognitive symptoms who never had GI complaints — were not entered into H. pylori studies. They were not the population the research was designed to capture.
This creates a classic ascertainment bias: the absence of evidence that H. pylori causes systemic downstream conditions in the "asymptomatic" population is partly a consequence of never having systematically tested that population. The patients most likely to have H. pylori-associated iron deficiency, Hashimoto's, or chronic hives were never in the studies looking for H. pylori associations — because they were presenting to hematologists, endocrinologists, and dermatologists, not gastroenterologists.
The more accurate statement is: most H. pylori-positive individuals do not develop symptoms currently recognized as GI manifestations of H. pylori disease. Whether they are developing other conditions in which H. pylori plays an upstream role is a different question — one that has only recently begun to be investigated systematically, and which this page documents in Section III. The absence of GI symptoms is not evidence of biological inertness.
H. pylori is not one thing. Hundreds of complete genomes have been sequenced, and the genetic diversity within the species is substantial. Two people infected with H. pylori can have dramatically different biological experiences depending on the specific strain they carry. Understanding this variation is essential for understanding why not every infected person develops downstream complications — and why the downstream risk picture is more concentrated than a raw prevalence figure suggests.
CagA — the primary virulence determinant. The most clinically significant strain variation involves the CagA gene (cytotoxin-associated gene A). Strains are broadly classified as CagA-positive or CagA-negative. CagA-positive strains possess a type IV secretion system — essentially a molecular syringe — that injects the CagA protein directly into gastric epithelial cells (Tegtmeyer N, et al. FEBS J. 2011).[1][9][10] Once inside the host cell, CagA disrupts multiple cellular signaling pathways, activating the NF-κB inflammatory cascade and increasing production of IL-8, TNF-alpha, and other pro-inflammatory cytokines. The result is a significantly more inflammatory infection with higher risk of peptic ulcer disease, gastric cancer progression, and — relevant to Section III — the systemic downstream effects that depend on chronic inflammation and molecular mimicry as their mechanism. CagA-negative strains are generally less inflammatory and carry lower downstream risk. CagA positivity rates in Western populations represent approximately 60–70% of H. pylori isolates (Covacci A, et al. Science. 1999;284(5418):1328–1333).[9]
VacA — additional virulence variation. VacA (vacuolating cytotoxin A) is a second major virulence factor with significant allelic variation. Different VacA alleles — classified by the signal region (s1 or s2) and mid-region (m1 or m2) — produce different levels of toxin activity. The s1/m1 combination is most virulent; s2/m2 is least.
Outer membrane proteins. BabA and SabA are outer membrane protein adhesins that affect how tightly H. pylori adheres to the gastric epithelium. Higher-adherence strains have more opportunity to inject CagA and generate local inflammation. BabA-positive strains are associated with higher ulcer and cancer risk.
What this means in practice. A national prevalence figure of 30% does not mean 30% of Americans are at equal risk of downstream complications. The downstream risk is concentrated in the fraction of that 30% carrying CagA-positive, VacA s1/m1, BabA-positive strains. Standard consumer testing — monoclonal stool antigen, urea breath test — detects H. pylori presence but not strain. Strain-specific testing is discussed in Section IV.
The standard picture of H. pylori damage — stomach inflammation leading to ulcers leading to cancer — is accurate but incomplete. It describes what happens locally, in the gastric mucosa, over time. It does not describe what happens systemically, throughout the body, through the same infection operating through four distinct biological mechanisms simultaneously.
This section documents those four mechanisms, then addresses two concepts essential to interpreting the condition-specific evidence in Section III: the gastric acid paradox (why the same infection can produce opposite physiological effects in different patients), and the causation question (how to read the evidence honestly, and what the intervention studies actually establish).
The mechanisms documented in this section generate hypotheses and explain observed associations. What establishes clinical relevance is the intervention evidence — what happens when the infection is eradicated. That evidence is in Section III.
H. pylori does not confine its inflammatory effects to the stomach. From the moment it establishes colonization, it generates a systemic cytokine burden that circulates throughout the body and has documented effects in organs far removed from the gastric mucosa.
The mechanism begins with CagA. When CagA is injected into gastric epithelial cells via the type IV secretion system, it activates the NF-κB inflammatory signaling pathway, triggering the release of interleukin-8 (IL-8) (Tegtmeyer N, et al. FEBS J. 2011;278(8):1190–1202). IL-8 recruits neutrophils to the gastric mucosa. Those neutrophils then release a cascade of pro-inflammatory cytokines — TNF-alpha, IL-1beta, and IL-6 — into systemic circulation. The result is a chronic, low-grade systemic inflammatory state that does not resolve while the infection remains active.
This systemic cytokine burden is not hypothetical. It is measurable in the blood of H. pylori-positive individuals and has been documented to resolve following successful eradication in controlled studies. Its downstream consequences are proportional to both infection duration and the presence of CagA-positive strains, which drive a meaningfully higher cytokine burden than CagA-negative strains.
CagA activates NF-κB through multiple convergent pathways including SHP-2-mediated RAS-ERK activation and direct IκB degradation. The resulting cytokine cascade — IL-8, TNF-α, IL-1β, IL-6 — is detectable in systemic circulation in H. pylori-positive individuals and is not confined to the gastric microenvironment. TNF-α and IL-6 cross the blood-brain barrier via specific saturable transport mechanisms documented in the neuroinflammation literature (Miller AH, et al. Biol Psychiatry. 2009;65(9):732–741).[11] TNF-α interferes with insulin receptor substrate-1 (IRS-1) serine phosphorylation, reducing downstream insulin signaling — a mechanism independently associated with insulin resistance in multiple metabolic studies. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generated by recruited neutrophils cause oxidative DNA damage in gastric epithelial cells, contributing to the mutagenic cascade underlying gastric cancer progression.
The second mechanism explains how a gastric bacterium triggers immune attacks on the thyroid, skin, platelets, and nervous system — organ systems with no obvious anatomical connection to the stomach.
H. pylori surface proteins, particularly CagA, contain structural epitopes — protein sequences — that share homology with several human tissue antigens. When the immune system generates antibodies against these H. pylori proteins, those antibodies can cross-react with the structurally similar human tissue. The immune system, unable to distinguish between the bacterial protein and the host tissue it resembles, attacks both. This process is called molecular mimicry, and it is a documented mechanism of autoimmune activation across multiple conditions — not a speculative one.
The specific tissue antigens with documented homology to H. pylori surface proteins include: platelet surface antigens GPIIb/IIIa (the proposed mechanism of H. pylori-associated immune thrombocytopenic purpura); thyroid peroxidase and thyroglobulin (the proposed mechanism of H. pylori-associated Hashimoto's thyroiditis and Graves' disease); skin mast cell surface antigens (the proposed mechanism of H. pylori-associated chronic spontaneous urticaria); gastric parietal cell H+/K+-ATPase (the proposed mechanism of H. pylori-associated B12 malabsorption through intrinsic factor impairment); and neural tissue antigens via VacA structural homology, contributing to peripheral nerve effects (Tegtmeyer N, et al. FEBS J. 2011).
A 2024 Mendelian randomization study by Wang et al. in Science Advances[12] has strengthened the autoimmunity hypothesis for thyroid disease — providing genetic evidence for a causal direction (specifically for Graves' disease and hyperthyroidism) that goes beyond observational association.
CagA contains EPIYA motifs with structural homology to GPIIb/IIIa platelet surface antigens — the basis of the molecular mimicry model for H. pylori-associated ITP. Anti-CagA antibodies have been documented to cross-react with platelet surface proteins in ITP patients, and platelet counts recover following eradication in roughly half of cases across controlled trials — consistent with removal of the antigenic stimulus. CagA epitopes also share structural homology with thyroid peroxidase (TPO) and thyroglobulin; anti-TPO antibody titers decrease following eradication in multiple controlled studies (Bertalot G, et al. Clin Endocrinol (Oxf). 2004;61(5):650–652).[13] VacA structural homology with neural antigens is proposed as a mechanism for peripheral nerve effects. The LPS O-antigen of H. pylori mimics Lewis blood group antigens on the gastric epithelium — an immune evasion mechanism that also has autoimmune implications in susceptible individuals. Molecular mimicry-driven autoimmunity requires host genetic susceptibility (HLA type and immune regulation variants) — which explains why only a subset of CagA-positive H. pylori carriers develop thyroid autoimmunity, urticaria, or ITP.
The third mechanism is the most directly actionable — and the one with the strongest interventional evidence base. H. pylori interferes with the absorption of both iron and vitamin B12 through distinct but related pathways, creating nutritional deficiencies that do not respond to supplementation while the infection remains active.
Iron depletion — two pathways. The first pathway involves transferrin receptor mislocalisation. CagA and VacA, acting synergistically, are reported to mislocalize the transferrin receptor from its normal position on the basolateral surface of intestinal epithelial cells to the apical surface — effectively redirecting the host's iron transport machinery toward the bacterium rather than toward systemic absorption (Tan S, et al. PLoS Pathog. 2011;7(5):e1002050).[14] The second pathway operates through ascorbic acid depletion. H. pylori depletes ascorbic acid (vitamin C) in the gastric lumen by an estimated 50–80% relative to uninfected individuals. Ascorbic acid is required for the reduction of dietary non-heme iron from its poorly absorbed ferric form (Fe3+) to its absorbable ferrous form (Fe2+). Without sufficient ascorbic acid, non-heme iron passes through the gut largely unabsorbed.
The clinical consequence of these two combined mechanisms is iron deficiency that does not respond to supplementation. Across seven randomized trials enrolling 956 patients, adding H. pylori eradication to iron supplementation raised iron stores (ferritin) more reliably than iron supplementation alone, with a smaller and less consistent effect on hemoglobin (Hudak L, et al. Helicobacter. 2017;22(1):e12330).[15][16]
B12 depletion — a progressive pathway. B12 depletion follows a different route. H. pylori causes progressive inflammation of the gastric corpus where parietal cells reside. Parietal cells produce intrinsic factor, the protein that binds dietary B12 in the stomach and escorts it to absorption sites in the ileum. Without intrinsic factor, dietary B12 cannot be absorbed regardless of how much is consumed. In H. pylori-positive patients with corpus-predominant gastritis and progressive atrophic changes, parietal cell function declines over time. The resulting B12 deficiency develops slowly — B12 stores can last years — but once established, it produces neurological consequences including peripheral neuropathy, cognitive impairment, and mood disturbance that may not be recognized as B12-related until the deficiency is severe.
Iron pathway detail: CagA and VacA synergistically mislocalize the transferrin receptor from the basolateral to the apical surface of intestinal epithelial cells at bacterial microcolony sites, directing iron toward the bacterium rather than systemic circulation (Tan S, et al. PLoS Pathog. 2011;7(5):e1002050). Ascorbic acid depletion reduces Fe3+→Fe2+ conversion — non-heme iron requires this reduction for absorption via DMT1 at the brush border. H. pylori depletes gastric luminal ascorbic acid by an estimated 50–80%; the mechanism involves both consumption by the oxidative inflammatory environment and reduced secretion by inflamed gastric epithelium. Meta-analytic evidence for iron: Hudak et al., Helicobacter 2017 — association with iron-deficiency anemia OR 1.72 (95% CI 1.23–2.42, 14 observational studies); across 7 RCTs (956 patients), eradication added to iron raised ferritin (SMD 0.53, 95% CI 0.21–0.85) but the hemoglobin difference did not reach statistical significance (SMD 0.36, 95% CI −0.07 to 0.78, p≈0.1).
B12 pathway detail: H. pylori-induced corpus gastritis produces progressive parietal cell atrophy via CagA-driven NF-κB activation and VacA-induced mitochondrial apoptosis. The H. pylori urease beta-subunit shares structural homology with parietal cell H+/K+-ATPase, generating cross-reactive anti-parietal cell antibodies — an autoimmune mechanism compounding the inflammatory atrophy. Active B12 (holotranscobalamin) and functional B12 status (MMA) improve at 6–12 months post-eradication in B12-deficient patients (Kaptan K, et al. Arch Intern Med. 2000;160(9):1349–1353).
The enteric nervous system — the 500 million neurons embedded in the gastrointestinal tract — communicates bidirectionally with the central nervous system through the vagus nerve, the hypothalamic-pituitary-adrenal (HPA) axis, and systemic inflammatory signaling (Bercik P, et al. Gastroenterology. 2011;141(2):599–609).[17] H. pylori disrupts it through at least four documented pathways simultaneously.
Ghrelin and metabolic signaling disruption. H. pylori significantly reduces the density of ghrelin-producing cells in the gastric fundus. Ghrelin is a hormone with multiple functions beyond appetite regulation — it also modulates energy homeostasis, influences HPA axis activity, and has neuroprotective effects in the central nervous system. Reduced ghrelin production from H. pylori-damaged fundic cells alters appetite signaling, energy metabolism, and metabolic regulation in ways that contribute to both fatigue and metabolic syndrome associations documented in Section III.
Systemic cytokine access to the CNS. The same TNF-alpha, IL-6, and IL-1beta generated by Mechanism 1 cross the blood-brain barrier via saturable transport mechanisms. Once inside the CNS, these cytokines trigger neuroinflammation associated with cognitive symptoms, fatigue, mood dysregulation, and reduced processing speed. This is not a speculative pathway; cytokine-induced neuroinflammation is a well-characterized phenomenon with an extensive research base in depression, chronic fatigue, and cognitive impairment (Miller AH, et al. Biol Psychiatry. 2009;65(9):732–741).[11]
VacA neural tissue effects. VacA shares structural homology with neural tissue antigens — a molecular mimicry pathway that generates antibodies capable of cross-reacting with peripheral nerve tissue. This contributes to peripheral neuropathy symptoms in some H. pylori-positive patients.
Enteric neurotransmitter disruption. H. pylori infection alters the production of neurotransmitters in the enteric nervous system, including serotonin precursors. The enteric nervous system produces approximately 90% of the body's serotonin — a neurotransmitter with functions that extend far beyond the gut, including regulation of mood, sleep, and cognitive function.
Ghrelin cell density in the gastric fundus is significantly reduced in H. pylori-positive individuals compared to controls in multiple studies; density increases following eradication, contributing to the observed metabolic improvements post-treatment. Systemic cytokine CNS access: TNF-α and IL-6 are transported across the blood-brain barrier via specific receptor-mediated mechanisms — not passive diffusion. CNS cytokine exposure activates microglia, reduces BDNF production, and interferes with hippocampal neurogenesis — pathways implicated in depression, cognitive impairment, and fatigue (Dinan TG, Cryan JF. Gastroenterol Clin North Am. 2017;46(1):77–89).[18] The neurological associations of H. pylori are classified as MODERATE — the mechanistic case is strong; the interventional evidence from eradication studies is consistent but drawn from smaller and less standardized trials than the iron and ITP evidence base.
Correa's Cascade, described by Colombian pathologist Pelayo Correa in the 1970s, is the staged progression from H. pylori infection to gastric adenocarcinoma. It is one of the best-characterized cancer development sequences in medicine — a sequential, staged process that takes years to decades to complete and is, at its early stages, reversible with eradication.
The stages: (1) H. pylori infection — initial colonization, typically acquired in childhood; (2) Chronic non-atrophic gastritis — persistent inflammation without structural damage; (3) Atrophic gastritis — progressive loss of parietal cells and glandular tissue (this stage also produces B12 malabsorption through reduced intrinsic factor production); (4) Intestinal metaplasia — replacement of gastric epithelium with intestinal-type cells; (5) Dysplasia — pre-malignant cellular changes; (6) Gastric adenocarcinoma.
Eradication at stages 1–3 can halt or reverse progression, and randomized trials show eradication reduces subsequent gastric cancer incidence (Ford AC, et al. BMJ. 2014;348:g3174).[19] At stage 4 and beyond, the benefit of eradication for cancer prevention is less certain — the structural changes may have passed the point of reversibility. This is why early detection and treatment matter: the infection's cancer risk compounds with time, and the window in which eradication is most protective is early in the progression sequence.
Two additional notes relevant to this page: First, the atrophic gastritis at stage 3 is the same pathological process that drives B12 malabsorption — parietal cell destruction reduces intrinsic factor production. The cancer progression pathway and the systemic nutritional consequence share the same underlying mechanism. Second, the gastric acid paradox — described next — explains why patients at different stages of Correa's Cascade have different acid physiologies, and why this matters for both symptoms and testing.
One of the most clinically important and least-explained aspects of H. pylori is that it can produce opposite effects on gastric acid secretion depending on where in the stomach it colonizes and how advanced the gastric damage is. This explains why two people with the same infection can have completely different symptom profiles — and why some patients present with severe reflux and ulcers while others present with malabsorption and SIBO-like symptoms.
Direction 1 — Antrum-predominant colonization: acid excess. When H. pylori colonizes predominantly in the antrum, it stimulates G cells in that region to release gastrin. Gastrin drives parietal cells in the fundus to produce more acid. The result is acid hypersecretion producing conditions favorable for duodenal ulcer formation and the severe gastric symptoms most people associate with H. pylori infection. These patients typically have heartburn, upper GI pain, duodenal ulcers, reflux symptoms. Their B12 and iron absorption are often relatively preserved because parietal cell function is intact or hyperactive.
Direction 2 — Corpus-predominant colonization with atrophic gastritis: acid deficiency. When H. pylori colonizes predominantly in the corpus and causes progressive atrophic gastritis, it destroys parietal cells over time, producing hypochlorhydria (reduced acid) or, in advanced cases, achlorhydria (near-absent acid). These patients typically have: reduced or absent GI symptoms (paradoxically — less acid means less pain), but progressive downstream consequences including iron malabsorption, B12 malabsorption, and altered gut microbiome composition. This is the population most likely to present with the downstream conditions documented in Section III — iron deficiency, B12 deficiency, fatigue, cognitive symptoms — without prominent GI complaints.
The PPI interaction. PPIs suppress gastric acid regardless of the direction H. pylori has pushed acid secretion. In corpus-predominant patients who already have hypochlorhydria from atrophic gastritis, PPIs reduce acid further — worsening iron absorption, B12 absorption, and magnesium absorption in a patient whose malabsorption mechanisms are already impaired by the infection itself. A patient who is prescribed long-term PPIs for residual gastric symptoms, who actually has corpus-predominant H. pylori with progressive atrophic gastritis, may be receiving a treatment that manages a symptom while worsening the underlying mechanism responsible for their iron deficiency, B12 decline, and fatigue.
Antrum-predominant H. pylori: elevated gastrin → parietal cell hyperplasia → acid hypersecretion → duodenal ulcer risk, lower cancer risk. Corpus-predominant H. pylori with atrophic gastritis: progressive parietal cell loss → reduced acid output → achlorhydria in advanced cases → iron and B12 malabsorption → higher gastric cancer risk (atrophic gastritis is stage 3 of Correa's Cascade). The Operative Link for Gastritis Assessment (OLGA) and OLGIM staging systems stratify gastric cancer risk based on the extent and distribution of atrophy and intestinal metaplasia across antrum and corpus — the clinical tool for identifying corpus-predominant patients at highest progression risk. PPIs: both omeprazole and esomeprazole suppress parietal cell acid secretion via irreversible H+/K+-ATPase inhibition — reducing gastric acid by 80–95% at standard doses. In corpus-predominant patients with already-reduced parietal cell mass, PPI-driven further acid suppression meaningfully compounds the iron and B12 malabsorption already present.
Association means two things tend to occur together. Causation means one produces the other. Much of the H. pylori extra-gastric evidence base is associational: H. pylori-positive individuals have higher rates of iron deficiency, thyroid autoimmunity, chronic hives, and other conditions. That association is consistent and replicated. But association alone does not establish causation.
Three competing explanations for any association. (1) H. pylori causes the downstream condition — the hypothesis Welyon investigates. (2) Reverse causation — the downstream condition predisposes to H. pylori. Iron deficiency alters gastric mucosa in ways that may facilitate H. pylori colonization. (3) Confounding — a third factor causes both. Lower socioeconomic status increases both H. pylori acquisition risk and iron deficiency through nutritional pathways.
Why eradication RCT evidence cuts through this. A randomized controlled trial that assigns H. pylori-positive patients to eradication versus no eradication and measures downstream outcomes directly addresses the association problem. If eradication added to iron raises iron stores better than iron supplementation alone — as randomized trials demonstrate — that is not association. That is an intervention changing a measurable outcome.
Where each condition sits on the hierarchy. Evidence for H. pylori's downstream associations spans multiple levels: observational association, prospective cohort, randomized controlled trial, and Mendelian randomization (which uses genetic variants associated with H. pylori susceptibility as natural instruments to test causal direction — considered among the strongest available evidence for causation in human populations).
| Condition | Strongest evidence type | Tier | Key finding |
|---|---|---|---|
| Iron deficiency | Randomized trials, meta-analysis | Strong | Eradication + iron raises iron stores (ferritin) more reliably than iron alone; ~1.7× odds of IDA in carriers (Hudak et al., 2017) |
| ITP | Controlled trials + ASH guideline | Strong | Platelet recovery in roughly half of H. pylori-positive patients post-eradication |
| Chronic urticaria | 9 RCTs, meta-analysis | Moderate | Higher remission after eradication across pooled RCTs (Watanabe et al., 2021) |
| B12 deficiency | Meta-analysis, 10 cohorts | Moderate | MMA and holotranscobalamin improvement at 6–12 months |
| Thyroid autoimmunity | Mendelian randomization + meta-analysis | Moderate | ~2× higher H. pylori prevalence; genetic causal evidence for Graves'/hyperthyroidism (Wang et al., Sci Adv, 2024) |
| Fatigue | Cohort studies (downstream of iron/B12) | Moderate | Fatigue score improvement reported in small studies (validated instruments) |
| Brain fog | Longitudinal cohort | Moderate | Cognitive improvement reported in small studies (validated instruments) |
| Metabolic syndrome | Meta-analysis, 18 studies | Exploratory | ~1.3× higher odds of metabolic syndrome in carriers (Upala et al., 2016) |
The honest Welyon position. For some conditions the causal case is strong — iron deficiency and ITP have RCT-level evidence that places them as close to established causation as clinical research allows without genetic manipulation. For others, the association is real, the mechanism is plausible, and the eradication evidence is promising — but certainty is not claimed. H. pylori is a documented upstream contributor to these conditions in a meaningful subset of people who have them. Not the only cause. Not a guaranteed cause in every positive patient. A frequently missed upstream factor worth investigating.
The conditions below have documented associations with H. pylori in the peer-reviewed literature. Each entry covers the clinical picture, the mechanism, the evidence, and what the gap looks like in practice. Evidence is graded using the same three-tier rubric applied across all Welyon investigation guides — Strong, Moderate, or Exploratory — applied identically regardless of commercial interest.
Strong reflects replicated RCT or meta-analytic data. Moderate reflects consistent cohort evidence with some interventional support. Exploratory reflects early mechanistic or observational work. The evidence hierarchy framework for reading these entries is in Section II (§ 2.7). Where guideline endorsement exists, it is noted. Where the evidence has limitations, those limitations are stated.
The clinical picture
Iron deficiency anemia affects more than 10 million Americans. It is the most common nutritional deficiency globally and one of the most commonly mismanaged — not because the treatment is complicated, but because the treatment is frequently applied without investigating the cause. The signature presentation that should prompt H. pylori investigation is refractory iron deficiency: iron levels that do not respond to supplementation, or that return to deficient levels after supplementation stops. This pattern indicates an active depletion mechanism that supplementation cannot address while the source remains present.
The mechanism
Two pathways operate simultaneously (Section II, Mechanism 3). CagA and VacA mislocalize the transferrin receptor, directing iron toward the bacterium rather than systemic absorption; and H. pylori depletes ascorbic acid in the gastric lumen by an estimated 50–80%, impairing the Fe3+→Fe2+ conversion required for non-heme iron absorption. Both mechanisms are active regardless of dietary iron intake. Supplementation adds iron to a system that is actively being disrupted. Eradication removes the disruption.
The evidence
Multiple randomized controlled trials have examined H. pylori eradication in iron-deficient patients. Pooled across seven of the most rigorous of these trials (956 patients), adding eradication to iron supplementation raised iron stores (ferritin) more reliably than iron supplementation alone; the effect on hemoglobin was smaller and did not reach statistical significance (Hudak L, et al. Helicobacter. 2017;22(1):e12330).[15][16] This is RCT-level interventional evidence — among the highest standards of clinical proof available without genetic manipulation. Testing for H. pylori is increasingly recommended as part of the evaluation for unexplained iron deficiency anemia.
The gap
Hematologists and primary care physicians treating iron deficiency do not routinely test for H. pylori in the absence of GI symptoms. The standard approach is to treat the deficiency with iron supplementation and investigate for blood loss. H. pylori's malabsorption mechanisms are not part of the standard diagnostic algorithm despite randomized-trial evidence demonstrating their clinical significance.
→ The Iron Deficiency Investigation GuideStudy: Hudak L, et al. Updated systematic review and meta-analysis on the association between H. pylori infection and iron deficiency anemia. Helicobacter. 2017;22(1):e12330. Design: meta-analysis; 14 observational studies (association) and 7 RCTs, 956 patients (intervention). Finding: iron-deficiency-anemia association OR 1.72 (95% CI 1.23–2.42); eradication added to iron raised ferritin (SMD 0.53, 95% CI 0.21–0.85) but the hemoglobin difference did not reach significance (SMD 0.36, 95% CI −0.07 to 0.78).
Study: Hudak et al., Helicobacter, 2017 · Design: Meta-analysis, 7 RCTs, 956 patients · Finding: eradication + iron raised iron stores (ferritin) more reliably than iron alone; hemoglobin effect not significant; ~1.7× odds of IDA in carriers · Tier: Strong · Source class: Meta-analysis of RCTs
The clinical picture
Immune thrombocytopenic purpura (ITP) is an autoimmune condition in which the immune system produces antibodies that target and destroy platelets, producing abnormally low platelet counts and bleeding risk. It affects approximately 25,000 adults in the United States at any given time. ITP is treated with corticosteroids, intravenous immunoglobulin, and in refractory cases, splenectomy or immune-modulating agents. The standard treatment suppresses the immune response. It does not address the potential antigenic stimulus driving that response.
In H. pylori-positive ITP patients, removing the antigenic stimulus — through eradication — produces platelet recovery in roughly half of cases across multiple controlled trials.[20][21] Without any other intervention. This is one of the most striking demonstrations of H. pylori's systemic reach in the entire literature: an autoimmune hematological condition resolving after treating a gastric infection.
The mechanism
Molecular mimicry (Section II, Mechanism 2). CagA surface proteins contain epitopes structurally homologous to GPIIb/IIIa — a platelet surface antigen. Antibodies generated against CagA cross-react with platelet surfaces, triggering platelet destruction by the immune system. Eradication removes the CagA antigenic stimulus, cross-reactive antibody production declines, and platelets recover.
The evidence
Multiple controlled trials document platelet recovery in roughly half of H. pylori-positive ITP patients following eradication. Hematology guidelines support testing ITP patients for H. pylori — one of the few of the eight conditions where guideline support explicitly exists. Despite this, a 2021 international survey of 186 hematologists across 39 countries found that only 29% always test ITP patients for H. pylori (Vishnu P, et al. J Thromb Haemost. 2021;19(1):287–296).[22]
The gap
This is the starkest example of the guideline-practice gap in the entire H. pylori literature. The evidence is strong. The guideline endorsement is explicit. The test is inexpensive and non-invasive. Yet the majority of ITP patients in the US and globally are not being tested for H. pylori. The reason is structural — H. pylori testing is not embedded in hematology clinical workflows even when the professional society guideline recommends it.
→ The Immune Investigation GuideStudy: Stasi R, et al. Effects of eradication of H. pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009;113(6):1231–1240; Vishnu P, et al. J Thromb Haemost. 2021;19(1):287–296. Design: systematic review of controlled cohorts (platelet response); international survey of 186 hematologists, 39 countries (practice pattern). Finding: complete platelet response ~43% and overall response ~50% post-eradication (lower in severe baseline thrombocytopenia); 29% of surveyed hematologists always test ITP patients for H. pylori. Tier: Strong. Source class: Systematic review + practice-pattern survey.
Study: Stasi et al., Blood, 2009 (systematic review); Vishnu et al., J Thromb Haemost, 2021 (survey) · Design: Systematic review of controlled cohorts; international survey, 186 hematologists, 39 countries · Finding: platelet recovery in roughly half of patients post-eradication; only 29% of hematologists always test · Tier: Strong · Source class: Systematic review + survey
The clinical picture
Chronic spontaneous urticaria (CSU) — chronic hives without an identifiable external trigger — affects approximately 1% of the global population at any given time. It is characterized by recurrent wheals and itching lasting more than six weeks without a clear physical cause. The standard treatment is antihistamines, which manage symptoms but do not address the underlying mechanism in most patients. Many people with CSU remain on indefinite antihistamine maintenance — sometimes for years. The question this evidence raises is not whether antihistamines work for CSU. They do, for symptom management. The question is whether a subset of CSU patients have an upstream infectious trigger that antihistamines are suppressing without resolving.
The mechanism
Molecular mimicry (Section II, Mechanism 2). Anti-CagA antibodies cross-react with skin mast cell surface antigens, triggering mast cell degranulation and histamine release. VacA directly activates mast cell degranulation through a separate mechanism. The result is a chronic histamine release driven not by an external allergen but by an ongoing immune response to a gastric infection.
The evidence
Nine randomized controlled trials, enrolling 361 patients, have examined H. pylori eradication in CSU patients. Pooled across these trials, H. pylori-positive CSU patients who receive eradication therapy are more likely to enter remission than those who do not (Watanabe J, et al. Antibiotics. 2021;10(2):156).[23] One nuance complicates the causal picture: in a separate meta-analysis of 22 studies and 1,385 patients, remission tended to follow antibiotic therapy whether or not H. pylori was successfully eradicated, and H. pylori-negative patients showed higher spontaneous remission than positive patients — consistent with the infection maintaining the condition in a subset of carriers (Kim HJ, et al. Helicobacter. 2019;24(6):e12661).[24] A 2022 EAACI international guideline on urticaria makes a weak recommendation for H. pylori testing (Zuberbier T, et al. Allergy. 2022;77(3):734–766).[25] Within Welyon’s rubric this sits at the top of the Moderate tier — the best-evidenced of the conditions that fall short of Strong (nine RCTs, I²=0%), held back only by that eradication-independent remission signal.
The gap
H. pylori testing is not standard in dermatology or allergy workup for CSU. Patients are managed with antihistamines — often indefinitely — without upstream investigation. The response rate to eradication (approximately 30–50% of H. pylori-positive CSU patients achieving remission) is meaningful enough to warrant investigation in any patient with refractory CSU and no identified trigger.
→ The Skin & Chronic Hives Investigation GuideStudy: Watanabe J, Shimamoto J, Kotani K. The effects of antibiotics for Helicobacter pylori eradication or dapsone on chronic spontaneous urticaria: a systematic review and meta-analysis. Antibiotics (Basel). 2021;10(2):156. Design: meta-analysis, 9 RCTs, 361 patients. Finding: higher remission with eradication therapy (RR 3.99, 95% CI 1.31–12.14 — wide; I²=0%). Kim HJ, et al. Helicobacter. 2019;24(6):e12661. Design: meta-analysis, 22 studies, 1,385 patients. Finding: eradication therapy raised CSU remission (RR 2.10, 95% CI 1.20–3.68), but remission was not dependent on successful eradication (RR 1.00); HP-negative patients showed higher spontaneous remission. Guideline: EAACI 2022 — weak recommendation for testing. Tier: Moderate. Source class: Meta-analyses of RCTs.
Study: Watanabe et al., Antibiotics, 2021; Kim HJ et al., Helicobacter, 2019 · Design: Meta-analysis of 9 RCTs, 361 patients; 22-study meta-analysis, 1,385 patients · Finding: higher CSU remission with eradication therapy (RR 3.99, wide CI; Kim RR 2.10), though benefit may not depend on successful eradication · Tier: Moderate · Source class: Meta-analyses of RCTs
The clinical picture
Thyroid autoimmunity — including Hashimoto's thyroiditis and Graves' disease — is the most common autoimmune condition globally. In Hashimoto's, the immune system attacks the thyroid gland, progressively destroying thyroid tissue and impairing hormone production. In Graves', it drives excess thyroid hormone production. Both are managed primarily by managing the hormonal consequences — thyroid hormone replacement for Hashimoto's, anti-thyroid medications or radioactive iodine for Graves' — rather than by investigating potential upstream triggers. H. pylori is one of those potential triggers — not the only one, not a guaranteed cause in every patient, but a documented upstream factor in a meaningful proportion of cases that is essentially never investigated in standard endocrinology practice.
The mechanism
Molecular mimicry (Section II, Mechanism 2). CagA surface proteins share structural homology with thyroid peroxidase (TPO) and thyroglobulin — the primary antigens targeted in Hashimoto's thyroiditis. Antibodies generated against CagA cross-react with thyroid tissue, contributing to the anti-TPO and anti-thyroglobulin antibody burden that drives thyroid inflammation and destruction. The association is stronger in CagA-positive strains than CagA-negative strains — consistent with the molecular mimicry hypothesis, since CagA is the protein carrying the homologous epitopes.
The evidence
A meta-analysis by Hou et al. in Oncotarget pooled 15 studies (3,046 total subjects — 1,716 with autoimmune thyroid disease and 1,330 controls). H. pylori infection was roughly twice as common in people with autoimmune thyroid disease, and the association was stronger for CagA-positive strains — consistent with the mimicry hypothesis (Hou Y, et al. Oncotarget. 2017;8(70):115691–115700).[26] Multiple studies document reduction in thyroid (TPO) antibody levels following eradication (Bertalot G, et al. Clin Endocrinol (Oxf). 2004;61(5):650–652).[13] A 2024 bidirectional Mendelian randomization study by Wang et al. in Science Advances found genetic evidence for a causal link specifically with Graves' disease and hyperthyroidism — and a reverse effect of hyperthyroidism on H. pylori antibody levels (Wang K, et al. Sci Adv. 2024;10(31):eadi8646).[12] The evidence is classified as Moderate because eradication does not improve thyroid autoimmunity in all patients and the interventional evidence base has more variability than the iron and ITP evidence.
The gap
H. pylori does not appear in any endocrinology guideline for Hashimoto's or Graves' disease. A rough extrapolation from US prevalence and the observed association suggests on the order of a few million Americans could have H. pylori-associated thyroid autoimmunity without having been tested for the infection. The test is inexpensive. The test is non-invasive. The question is never asked.
→ The Thyroid Investigation GuideStudy: Hou Y, et al. Meta-analysis of the correlation between H. pylori infection and autoimmune thyroid diseases. Oncotarget. 2017;8(70):115691–115700. Design: meta-analysis, 15 studies, 3,046 subjects (1,716 cases, 1,330 controls). Finding: OR 2.25 (95% CI 1.72–2.93) for H. pylori positivity in autoimmune thyroid disease; CagA-positive OR 1.99 (95% CI 1.07–3.70). Wang K, et al. Sci Adv. 2024;10(31):eadi8646. Design: bidirectional Mendelian randomization. Finding: anti-outer-membrane-protein antibodies causally associated with increased risk of hyperthyroidism and Graves' disease; reverse MR found hyperthyroidism raised CagA/OMP antibody levels. Bertalot G, et al. Clin Endocrinol (Oxf). 2004;61(5):650–652. Finding: decreased TPO antibody titres following eradication. Tier: Moderate. Source class: Meta-analysis + Mendelian randomization + eradication-outcome study.
Study: Hou et al., Oncotarget, 2017 (15 studies, 3,046 subjects); Wang K et al., Sci Adv, 2024 (Mendelian randomization) · Finding: ~2× higher HP prevalence in thyroid autoimmunity (OR 2.25); genetic causal evidence for Graves'/hyperthyroidism; TPO antibody reduction post-eradication · Tier: Moderate · Source class: Meta-analysis + Mendelian randomization
The clinical picture
Fatigue that sleep does not fix — fatigue that persists despite normal thyroid panels, normal CBC, normal metabolic workup — is one of the most common presenting complaints in primary care and one of the most difficult to investigate systematically. The standard response is to rule out the obvious causes (anemia, thyroid dysfunction, depression, sleep apnea) and, if those are normal, to attribute the fatigue to lifestyle factors or nonspecific causes. H. pylori is not on the standard differential for unexplained fatigue.
The mechanism
H. pylori-associated fatigue is not a single mechanism — it is the downstream consequence of multiple overlapping pathways operating simultaneously: chronic systemic cytokine burden (TNF-alpha, IL-6) impairing cellular energy metabolism and HPA axis regulation; iron deficiency reducing oxygen-carrying capacity and cellular energy production; B12 deficiency impairing mitochondrial energy metabolism; and gut-brain axis disruption affecting sleep quality, mood regulation, and neurological function. In patients with corpus-predominant H. pylori and progressive atrophic gastritis, all four pathways may be active concurrently.
The evidence
The fatigue evidence is best understood as downstream of the iron and B12 associations rather than as a standalone fatigue-specific claim. Small studies using validated fatigue instruments — including the Chalder Fatigue Scale[27] — report improvement in fatigue scores in H. pylori-positive patients following successful eradication, with the degree of improvement tending to track pre-treatment iron and B12 deficiency. No large fatigue-specific meta-analysis exists; the fatigue case rests largely on the iron and B12 evidence. The evidence is classified as Moderate — and explicitly weaker than the evidence for iron deficiency and ITP. The studies are smaller and less standardized, fatigue is inherently multifactorial, and the contribution of H. pylori in any individual patient depends on their specific iron status, B12 status, and infection burden. The mechanistic pathways are well-documented; the clinical evidence requires further interventional study.
The gap
No specialty includes H. pylori testing on the standard differential for unexplained fatigue. Patients are typically investigated for thyroid disease and anemia — and if those are "normal," the workup stops. The H. pylori question is not asked.
→ The Fatigue Investigation GuideInstruments: Chalder Fatigue Scale (Chalder T, et al. J Psychosom Res. 1993;37(2):147–153) and PHQ composites. Finding: small cohort studies report fatigue-score improvement post-eradication in H. pylori-positive patients, with improvement tending to track pre-treatment iron and B12 deficiency severity. Note: no large fatigue-specific meta-analysis exists; the fatigue case rests largely on the iron and B12 evidence base. Tier: Moderate. Source class: Cohort studies with validated instruments.
Design: Small cohort studies with validated instruments · Instruments: Chalder Fatigue Scale, PHQ composites · Finding: fatigue-score improvement post-eradication, tracking pre-treatment iron and B12 deficiency; no large fatigue-specific meta-analysis exists · Tier: Moderate · Source class: Cohort studies (downstream of iron/B12 evidence)
The clinical picture
Brain fog — difficulty concentrating, slow cognitive processing, word retrieval difficulty, reduced mental stamina — is a symptom complex that is consistently reported by patients and consistently underinvestigated clinically. Standard blood panels rarely reveal a cause. Brain imaging is typically normal. The standard clinical response is to attribute cognitive symptoms to stress, sleep, anxiety, or aging. The H. pylori-cognition connection is not about H. pylori directly infecting the brain. It is about a gastric infection generating systemic effects — cytokine burden, nutritional depletion, enteric neurotransmitter disruption — that reach the brain through documented pathways and produce measurable cognitive consequences.
The mechanism
Four pathways (Section II, Mechanism 4): systemic cytokines (TNF-alpha, IL-6) crossing the blood-brain barrier and triggering neuroinflammation; B12 deficiency impairing neurological function and myelination; VacA neural tissue effects via molecular mimicry; and enteric neurotransmitter disruption affecting CNS serotonin signaling. In patients with corpus-predominant atrophic gastritis, B12 depletion is often the primary driver of cognitive symptoms — and it develops slowly and silently over years before becoming clinically apparent.
The evidence
Small studies using validated cognitive and psychological instruments — including PHQ-9, GAD-7, and Chalder composite measures — report cognitive improvement following successful eradication in H. pylori-positive patients (Kountouras J, et al. J Neurol. 2009;256(5):758–767).[28] (That cohort studied Alzheimer’s disease specifically, so its applicability to everyday brain fog is indirect.) Cohort data also document progressive B12 deficiency in H. pylori-positive atrophic gastritis patients over time. The evidence is Moderate — and explicitly weaker than the evidence for iron deficiency and ITP. Cognitive symptoms are inherently difficult to measure with precision, the studies are smaller, and the interventional evidence is less standardized than in the higher-evidence categories. The mechanistic case is strong; the clinical proof is not yet at the same level.
The gap
No specialty includes H. pylori testing on the differential for brain fog or unexplained cognitive symptoms. The gut-brain axis connection — while mechanistically well-characterized and the subject of substantial academic research — has not translated into clinical testing protocols.
→ The Brain Fog Investigation GuideStudy: Kountouras J, et al. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. J Neurol. 2009;256(5):758–767. Design: cohort with eradication follow-up; validated cognitive instruments (MMSE, CAMCOG; PHQ-9/GAD-7/Chalder composites in related work). Finding: cognitive measures improved after successful eradication in H. pylori-positive patients; cohort data also show progressive B12 deficiency in HP-positive atrophic gastritis over time. Tier: Moderate. Source class: Cohort + validated-instrument outcome studies.
Study: Kountouras et al., J Neurol, 2009 · Design: Cohort with eradication follow-up; validated cognitive instruments · Finding: cognitive improvement after successful eradication; progressive B12 deficiency in HP+ atrophic gastritis · Tier: Moderate · Source class: Cohort study
The clinical picture
Metabolic syndrome — the cluster of insulin resistance, elevated fasting glucose, hypertriglyceridemia, low HDL, elevated blood pressure, and central obesity — affects approximately one in three American adults. It is managed primarily through lifestyle modification and, when those fail, pharmacological intervention. Its upstream causes are understood to include genetics, diet, sedentary behavior, and chronic low-grade inflammation. H. pylori fits into the chronic low-grade inflammation pathway — through a specific, documentable mechanism. The association is consistent across multiple pooled analyses; the causal direction is less established than in the iron and ITP categories.
The mechanism
Two primary pathways operate. First, the systemic cytokine cascade (Section II, Mechanism 1): TNF-alpha and IL-6 from H. pylori-driven inflammation interfere with insulin receptor substrate-1 (IRS-1) serine phosphorylation, reducing downstream insulin signaling and contributing to insulin resistance independently of diet or weight — a biochemical mechanism, not a lifestyle one. Second, ghrelin/leptin axis disruption (Section II, Mechanism 4): H. pylori's damage to ghrelin-producing cells in the gastric fundus alters appetite and energy metabolism signaling in ways that interact with metabolic regulation.
The evidence
H. pylori-positive individuals show consistently elevated rates of metabolic syndrome markers — fasting insulin, HOMA-IR, and metabolic syndrome diagnosis — compared to H. pylori-negative controls across multiple pooled analyses. Community and review data document higher insulin resistance in H. pylori-positive people (Chen LW, et al. PLoS One. 2015;10(5):e0128671; Polyzos SA, et al. Helicobacter. 2011;16(2):79–88),[29][30] and a meta-analysis of 18 studies found modestly higher odds of metabolic syndrome (about 1.3×) (Upala S, et al. J Dig Dis. 2016;17(7):433–440).[31] Modest insulin sensitivity improvement following eradication has been documented in some studies. The evidence is Exploratory — and the weakest causal case among the eight conditions. The association is primarily observational rather than interventional; the causal direction is not established; and socioeconomic confounding is a genuine methodological problem that has not been fully resolved. Readers who have found the iron deficiency and ITP evidence compelling should apply more skepticism here — the metabolic association is real and consistent, but the causal claim is substantially less certain.
The gap
H. pylori does not appear in any metabolic medicine, diabetes, or obesity guideline. The infectious contribution to insulin resistance — while mechanistically coherent and observationally consistent — remains outside the standard metabolic workup.
→ The Metabolic Investigation GuideStudy: Upala S, et al. Association between H. pylori infection and metabolic syndrome. J Dig Dis. 2016;17(7):433–440 (meta-analysis, 18 studies; metabolic syndrome OR 1.34, 95% CI 1.17–1.53); Chen LW, et al. PLoS One. 2015;10(5):e0128671; Polyzos SA, et al. Helicobacter. 2011;16(2):79–88. Finding: modestly higher odds of metabolic syndrome and higher insulin resistance (HOMA-IR) in HP-positive subjects; modest insulin sensitivity improvement post-eradication in some studies. Tier: Exploratory. Source class: Meta-analysis + observational cohorts. Note: socioeconomic confounding acknowledged; causal direction not definitively established.
Study: Upala et al., J Dig Dis, 2016; Chen et al., PLoS One, 2015; Polyzos et al., Helicobacter, 2011 · Design: Meta-analysis (18 studies) + observational cohorts · Finding: ~1.3× higher odds of metabolic syndrome in carriers; elevated fasting insulin and HOMA-IR · Tier: Exploratory · Source class: Meta-analysis + observational cohorts
The clinical picture
Vitamin B12 deficiency presents as a spectrum: at mild levels, fatigue and reduced mental stamina; at moderate levels, peripheral neuropathy (numbness, tingling, weakness in the hands and feet), mood disturbance, and cognitive impairment; at severe levels, irreversible neurological damage. Because B12 stores can last years, deficiency develops slowly and is often not identified until it has been present for a considerable time. The standard approach to B12 deficiency is to supplement — oral or injected B12 — which raises blood levels but does not address the absorption problem if intrinsic factor production remains impaired. Like iron supplementation in H. pylori-associated iron deficiency, B12 supplementation treats the deficiency but not the mechanism driving it.
The mechanism
Described in detail in Section II (Mechanism 3). The pathway is direct: H. pylori-induced corpus-predominant atrophic gastritis progressively destroys parietal cells, which produce intrinsic factor. Without intrinsic factor, dietary B12 cannot bind to ileal receptors for absorption. An additional molecular mimicry pathway generates antibodies against parietal cell ATPase, directly damaging intrinsic factor-producing cells. The result is B12 malabsorption that worsens over time as the atrophy progresses — regardless of dietary intake or oral supplementation.
The evidence
Cohort data show measurable improvement in methylmalonic acid (MMA) levels — a sensitive functional marker of B12 status — and holotranscobalamin (active B12) at 6–12 months following successful eradication in B12-deficient patients (Kaptan K, et al. Arch Intern Med. 2000;160(9):1349–1353).[32] The evidence is classified Moderate: the biological pathway is among the best-characterized of all eight conditions; the eradication outcome data are consistent; the evidence base is smaller than for iron deficiency but mechanistically more directly established.
The gap
Patients with B12 deficiency — and the neurological symptoms that result from it — are typically investigated for dietary insufficiency, pernicious anemia, and malabsorptive conditions. H. pylori is rarely included in that differential despite being a documented cause of intrinsic factor impairment through both inflammatory and autoimmune mechanisms. Neurologists treating peripheral neuropathy do not routinely test for H. pylori.
→ The Nerve & Energy Investigation GuideInstruments: MMA (methylmalonic acid), holotranscobalamin (active B12). Finding: measurable improvement in MMA and holotranscobalamin at 6–12 months post-eradication in B12-deficient patients (Kaptan K, et al. Arch Intern Med. 2000;160(9):1349–1353). H. pylori urease beta-subunit homology with parietal cell H+/K+-ATPase — autoimmune parietal cell damage mechanism (Tegtmeyer N, et al. FEBS J. 2011). Tier: Moderate. Source class: Cohort studies with functional B12 markers.
Study: Kaptan et al., Arch Intern Med, 2000 · Instruments: MMA, holotranscobalamin (active B12) · Finding: measurable improvement in MMA and holotranscobalamin at 6–12 months post-eradication in B12-deficient patients · Tier: Moderate · Source class: Cohort studies with functional B12 markers
This section covers everything involved in that detection — the history of how testing evolved, the current options and their accuracy, how to read results honestly, the risks of treatment, and the structural reasons why most people with H. pylori-associated conditions never get tested at all.
Before 1983, testing for H. pylori was not possible — the bacterium had not been formally described. Once Marshall and Warren established its role in peptic ulcers, the immediate diagnostic need was for a method that could confirm infection in ulcer patients. The only available option was endoscopy with biopsy — a specialist procedure requiring sedation, equipment, and clinical infrastructure. Accurate, but inaccessible for population-level testing.
The late 1980s produced the first accurate non-invasive option: the urea breath test (UBT). Based on the observation that H. pylori's urease enzyme breaks down urea into carbon dioxide, the UBT uses isotopically labeled urea to detect that CO₂ in exhaled breath — a direct marker of active urease activity and therefore active infection. The UBT remains the most accurate non-invasive test available.
The 1990s added the stool antigen test and the blood antibody (serology) test. The serology test became rapidly and widely used because it required only a blood draw and could be added to any standard panel. Convenience drove adoption. The accuracy problem — that antibody tests detect past exposure, not active infection, and remain positive for months to years after successful eradication — was acknowledged but largely ignored in clinical practice. Serology's footprint in clinical diagnostics outlasted its usefulness, and its legacy is a significant number of misclassified patients.
The 2000s and 2010s brought the monoclonal stool antigen test — a more specific version of the original stool antigen assay — which is now the recommended first-line non-invasive diagnostic by American College of Gastroenterology guidelines (Chey WD, et al. Am J Gastroenterol. 2024;119(9):1730–1753).[33] The most recent significant development is the PCR-based molecular stool test, which detects H. pylori DNA and simultaneously identifies clarithromycin resistance mutations.
The 2024 ACG guideline update formally deprecated clarithromycin triple therapy as first-line treatment due to resistance rates of 22–31% in the US (Ho JJC, et al. Am J Gastroenterol. 2022;117(8):1221–1230),[34] and introduced vonoprazan-based regimens as a new treatment class. This guideline change has not yet translated into widespread clinical practice change — more than half of US H. pylori patients continue to receive the deprecated clarithromycin-based regimen.
Understanding sensitivity and specificity. Sensitivity measures how well a test finds the disease when it's present: of all people who actually have H. pylori, what percentage does this test correctly identify as positive? A test with 93% sensitivity misses approximately 1 in 14 active infections — those are false negatives. Specificity measures how well a test avoids false alarms: of all people who don't have H. pylori, what percentage does this test correctly identify as negative? A test with 90% specificity incorrectly flags 1 in 10 uninfected people as positive.
| Test | Sensitivity | Specificity | Detects active infection | Notes |
|---|---|---|---|---|
| Monoclonal stool antigen | 90–94% | 90–94% | Yes | First-line recommended, 2024 ACG guideline |
| Urea breath test (C13/C14) | 95–96% | 95–96% | Yes | Gold standard non-invasive; measures active urease activity |
| Serology (IgG antibody) | 85–92% | 79–90% | No | Cannot distinguish active from past infection; not recommended for initial diagnosis by ACG |
| Endoscopy with biopsy | >95% | >95% | Yes | Appropriate when GI investigation clinically indicated; not appropriate as an H. pylori-specific test |
| PCR stool test (molecular) | >95% | >95% | Yes | Detects H. pylori DNA and predicts clarithromycin resistance simultaneously; available at specialty labs including Mayo Clinic Laboratories |
On the serology problem. The IgG antibody test remains widely used in clinical practice despite its known limitations. It detects antibodies against H. pylori — but antibodies persist for months to years after successful eradication. A patient who was treated and cleared five years ago may still test antibody-positive. For initial diagnosis, the 2024 ACG guideline recommends against serology as the primary test. For post-treatment confirmation, serology is entirely inappropriate — it will appear positive whether or not eradication was successful. Despite this, serology remains the most commonly ordered test in many primary care settings.
On PCR resistance testing. The PCR-based molecular stool test represents the most significant diagnostic advance in H. pylori testing in the past decade. It detects H. pylori DNA directly from stool and simultaneously identifies mutations associated with clarithromycin resistance — allowing the treating physician to select an appropriate eradication regimen before starting treatment rather than discovering treatment failure after completing a course. In an environment where clarithromycin resistance rates in the US approach 22–31%, prescribing a clarithromycin-based regimen without knowing resistance status means roughly 1 in 4 patients will fail their first treatment course.
Bismuth quadruple therapy (PPI + bismuth subcitrate + tetracycline + metronidazole) is now the preferred first-line regimen in areas with high clarithromycin resistance — which, at 22–31% nationally, is most of the United States. Bismuth has direct anti-H. pylori activity through membrane disruption and urease inhibition. This regimen is not new; it is now the recommended default rather than a second-line option.
Vonoprazan-based regimens represent a genuinely new treatment class. Vonoprazan is a potassium-competitive acid blocker (P-CAB) — a different mechanism from PPIs, producing stronger and more sustained acid suppression by blocking the potassium-binding site of H+/K+-ATPase rather than irreversibly binding it as PPIs do. Vonoprazan-amoxicillin dual therapy and vonoprazan-based triple therapy achieved eradication in roughly 80–85% of patients in a large US/European trial, and outperformed standard PPI triple therapy in clarithromycin-resistant infections (Chey WD, et al. Gastroenterology. 2022;163(3):608–619).[35] Both are now included in 2024 ACG recommendations.
Standard clarithromycin triple therapy (PPI + clarithromycin + amoxicillin) — the most commonly prescribed regimen in the US until the 2024 guideline change — is now formally deprecated as first-line in areas of high clarithromycin resistance. Eradication rates with this regimen fall to approximately 30% in resistant strains. Most US patients continue to receive it despite the guideline change.
Treatment duration: 14-day regimens significantly outperform 7-day regimens. A Cochrane systematic review found eradication rates of 81.9% at 14 days versus 72.9% at 7 days. All current guidelines recommend 14-day duration. When first-line treatment fails, confirmed by post-treatment testing, alternative regimens guided by antibiotic susceptibility testing are indicated.
PPI risks. Short-term PPI use for 14 days during eradication therapy carries a considerably lower risk profile than long-term maintenance PPI therapy. Long-term PPI use is associated with: magnesium deficiency; B12 malabsorption (compounding the B12 depletion that H. pylori itself may be causing via atrophic gastritis); iron malabsorption; increased C. difficile infection risk; potential increased fracture risk at high doses over years; and kidney disease associations documented in long-term cohort studies. There is also a rebound phenomenon: discontinuing PPIs after long-term use can produce rebound acid hypersecretion that makes symptoms temporarily worse — creating a dependency dynamic where stopping feels impossible even when the underlying condition may have resolved.
Antibiotic eradication therapy risks. Gut dysbiosis is the most significant concern: broad-spectrum antibiotics disrupt the gut microbiome, eliminating non-target bacteria alongside H. pylori. This disruption can persist for months after treatment completion. Probiotics added to eradication regimens reduce but do not eliminate this effect — the evidence for Lactobacillus rhamnosus GG, Lactobacillus reuteri, and Saccharomyces boulardii as adjuncts is reasonably strong for reducing side effects. C. difficile risk is real but low. Common side effects include nausea, diarrhea, metallic taste (from metronidazole), and abdominal discomfort. Amoxicillin carries allergy risk in penicillin-sensitive patients, who require alternative regimen selection.
The risk-benefit calculation. The risks of antibiotic eradication — 14 days, finite, well-characterized — are real. The risks of leaving H. pylori untreated are also real: progressive gastric damage following Correa's Cascade toward cancer, ongoing downstream systemic effects including iron depletion, B12 depletion, and autoimmune activation, and indefinite dependence on medications that manage consequences rather than causes. For most H. pylori-positive patients, the risk-benefit calculation favors eradication. The decision belongs to the patient and their clinician with full information on both sides.
Standard stool antigen and urea breath tests answer a binary question: is H. pylori present or absent? For most patients, this is the right first question. But the answer to a positive result is not the same for every patient — and knowing more about which type of H. pylori is present changes the risk picture meaningfully.
Strain-specific testing identifies the virulence characteristics of the infection — most importantly CagA status (positive or negative) and, in more detailed assays, VacA allele type. This information is not available from standard binary testing. It currently requires either endoscopic biopsy and culture or advanced molecular testing from stool samples. The clinical significance of this distinction is documented throughout this page: CagA-positive infections drive a considerably higher systemic downstream risk through molecular mimicry and more intensive cytokine production.
Welyon is developing a partnership to offer strain-specific stool testing that provides CagA status alongside the standard positive/negative result. (Partnership in development — this section will be updated when the testing pathway is live.)
What CagA status changes: Risk stratification is the primary value. A CagA-positive result means the infection carries meaningfully higher risk of downstream systemic effects — the molecular mimicry pathways for ITP, thyroid autoimmunity, and chronic urticaria are driven by CagA epitopes. It means more urgent priority on eradication, more rigorous confirmation testing post-treatment, and higher vigilance for downstream markers (iron, B12, TPO antibodies, platelet counts) even after confirmed eradication — because CagA-driven autoimmune processes may take time to reverse after the antigenic stimulus is removed. It also changes the clinical conversation — a patient who can say "I tested positive for H. pylori with a CagA-positive strain" is having a more specific and actionable conversation than one who says "I tested positive for H. pylori."
What CagA status does not currently change: Treatment regimen selection is not currently differentiated by CagA status in standard guidelines — the same antibiotic protocols are used regardless of strain. The PCR resistance test (which identifies antibiotic resistance mutations) is more directly actionable for regimen selection than CagA typing. The fundamental decision to treat is the same regardless of strain: all positive results warrant eradication. CagA status affects urgency and monitoring, not the basic treatment decision.
The honest framing: strain-specific testing answers "how seriously should I take this and what should I watch for?" rather than "what different treatment should I use?" That is still genuinely useful information — particularly for patients who also have one of the eight downstream conditions documented in Section III, where knowing CagA status informs how strongly to investigate the H. pylori connection.
Accurate H. pylori testing requires specific preparation. Failing to observe preparation requirements is the most common cause of false-negative results in clinical practice — producing a negative test result in a patient who actually has active H. pylori infection.
Why washout is required — the mechanism. PPIs suppress stomach acid. H. pylori, while acid-resistant, requires a certain level of gastric activity to maintain its full metabolic rate. When acid is suppressed by PPIs, H. pylori enters a reduced-activity state — it does not die, but its metabolic rate slows, it sheds fewer antigens into the stool, and its urease activity decreases. The stool antigen test detects antigens; the urea breath test detects urease activity. A suppressed infection produces less of both — producing a test result that reads negative even though the bacterium is still present. The same logic applies to antibiotics (they reduce bacterial load temporarily) and bismuth (direct anti-H. pylori activity). PPI use is extremely common in the populations most likely to want H. pylori testing — patients with chronic gastric symptoms, GERD, and acid-related conditions. The preparation requirement is rarely communicated clearly, and false-negative results from inadequate washout are a significant and underappreciated source of missed diagnoses in clinical practice.
| Medication | Washout period required | Why |
|---|---|---|
| Proton pump inhibitors (PPIs) | At least 14 days before testing | Suppress H. pylori metabolic activity; cause false negatives in both stool antigen and breath tests |
| Antibiotics | At least 28 days before testing | Reduce bacterial load temporarily; cause false negatives |
| Bismuth-containing compounds | At least 14 days before testing | Direct anti-H. pylori activity suppresses antigen shedding and urease production |
| H2 blockers (famotidine, ranitidine) | No washout required | Do not meaningfully affect stool antigen or breath test accuracy |
Many people are on PPIs or have recently taken antibiotics when they want to test. The practical question: does that mean they have to wait? Not necessarily — and there is an important asymmetry in what pre-washout results can tell you that is almost never explained to patients.
A positive result before completing washout is reliable. PPIs and antibiotics suppress H. pylori activity — they make the infection harder to detect. They cannot create a false positive. If you test positive while on a PPI, or within two weeks of stopping one, that positive result is genuine. The suppression mechanism only works in one direction: toward false negatives, not false positives. A positive pre-washout test means you have H. pylori.
A negative result before completing washout is ambiguous. A negative result while on a PPI, or shortly after stopping antibiotics, may be a true negative (you do not have H. pylori) or a suppressed positive (you do have H. pylori but the test could not detect it at this level of suppression). You cannot distinguish between these two possibilities from a single pre-washout negative result. The negative must be repeated after proper preparation before it can be relied upon.
The practical implication: Testing before washout and getting a negative does not mean you are clear. Testing before washout and getting a positive means you are positive. This is a meaningful clinical distinction that affects how patients should interpret their results — and it is almost never communicated clearly in clinical or consumer testing contexts.
Eradication of H. pylori is not guaranteed by completing a treatment course. Treatment failure rates are real: clarithromycin triple therapy fails in up to 22–31% of cases due to resistance; even bismuth quadruple therapy and vonoprazan-based regimens have intention-to-treat failure rates of 10–15%. A significant proportion of patients who believe they have been successfully treated still have active H. pylori infection.
The 2024 ACG guideline recommends confirmatory testing 4 weeks or more after completing treatment to verify eradication. Despite this recommendation, most patients treated for H. pylori in clinical practice are never retested. The consequence is invisible and significant: patients whose downstream conditions were driven by H. pylori may not improve after treatment — not because eradication doesn't work, but because treatment failed and the infection persists undetected.
Recommended confirmation testing: Test type — urea breath test (preferred post-treatment) or monoclonal stool antigen. Not serology: antibody tests remain positive regardless of eradication success. Timing: at least 4 weeks after completing the antibiotic course. PPI washout: at least 2 weeks without PPIs before the confirmation test — the same pre-washout logic applies. If the confirmation test is positive, a second-line regimen guided by antibiotic susceptibility testing is indicated.
At-home H. pylori testing is now available and, when processed by a CLIA-certified laboratory, produces accuracy comparable to clinical laboratory testing. The key distinction that matters is not whether the sample is collected at home — it is where the sample is processed. CLIA (Clinical Laboratory Improvement Amendments) certification is the federal standard for laboratory quality. A CLIA-certified laboratory processing an at-home stool antigen sample uses the same monoclonal assay class and the same quality controls as a clinical reference laboratory.
Who benefits most from at-home testing access: The patients most likely to benefit are precisely the patients least likely to receive H. pylori testing through standard clinical channels. A patient presenting to a dermatologist with chronic hives is not going to receive an H. pylori test order. A patient presenting to an endocrinologist with Hashimoto's is not going to receive an H. pylori test order. At-home testing gives these patients the ability to investigate independently and bring documented results into a clinical conversation — closing the access gap that the structural problem in § 4.11 creates.
Preparation requirements apply equally to at-home testing. The same PPI washout (14 days), antibiotic washout (28 days), and bismuth washout (14 days) requirements apply regardless of where the sample is collected. The pre-washout result logic (positive is reliable; negative is ambiguous) applies equally. Welyon's test kit uses a CLIA-certified US reference laboratory running monoclonal stool antigen detection — the same assay class used in clinical gastroenterology — with a plain-language patient report and preparation card included. Learn more about the Welyon test kit →
H. pylori testing is inexpensive, non-invasive, and highly accurate. The barrier to testing is not technical. The barrier is structural. Medicine is organized by organ system and specialty. A gastroenterologist manages stomach conditions. A hematologist manages blood disorders. An endocrinologist manages hormone and immune conditions. A dermatologist manages skin. An allergist manages immune responses. Each specialty has a diagnostic framework — a set of conditions and tests they consider when a patient presents with certain symptoms. H. pylori is not in the diagnostic framework of hematologists, endocrinologists, dermatologists, or allergists for the conditions documented in Section III.
The result is a systematic gap: patients are tested for H. pylori when they present with GI symptoms to a gastroenterologist. They are not tested when they present with the downstream conditions that H. pylori may be causing, to the specialists who manage those conditions. The ITP example is the starkest illustration: hematology guidelines support H. pylori testing in ITP patients. The guideline support exists. The evidence is strong. The test is simple. Yet in an international survey, 71% of hematologists did not always test ITP patients for H. pylori (Vishnu P, et al. J Thromb Haemost. 2021).[22]
Conservative estimates suggest 5–15 million Americans in the higher-evidence categories alone — iron deficiency, ITP — may have H. pylori-associated conditions while remaining untested. When moderate-evidence associations are included, that number may reach 20–35 million. This is not a failure of individual physicians. It is a structural consequence of how medicine is organized.
The gap is not scientific. The evidence base for H. pylori's systemic associations is peer-reviewed, replicated, and in some conditions formally guideline-endorsed. The knowledge exists. The problem is that it is not reaching the patients who need it, or consistently reaching the clinicians who treat them in non-gastroenterology settings.
Welyon was built specifically to address this gap. The H. pylori Investigation Series — eight condition-specific investigation guides, each documenting the peer-reviewed evidence for one downstream condition, explaining the mechanism, grading the evidence honestly, and giving patients a framework for investigation they can bring into a clinical conversation — is the primary educational product. Each guide applies the same three-tier evidence rubric across all eight conditions regardless of commercial interest. Each investigation guide is medically reviewed before publication.
The Japan model — described in Section I — shows what changes when the question is asked systematically at a national level: gastric cancer rates decline, testing becomes normalized, treatment is accessible and standard. The US equivalent of that systematic approach is not a government program. It is education at the patient level, giving individuals the information and the framework to ask a question that the standard healthcare system is often not asking for them. A patient who arrives at their specialist appointment knowing that randomized trials document H. pylori's role in refractory iron deficiency, or that hematology guidelines support H. pylori testing in ITP, is a patient who can ask an informed question and advocate for an appropriate test.
Clinicians: evidence summary and ordering pathways →Standard H. pylori eradication uses antibiotic combination regimens — triple or quadruple therapy, now increasingly vonoprazan-based. These regimens are effective when they work. The problem is that they don't always work, and for a meaningful proportion of patients they produce side effects significant enough to limit compliance or cause recurrence. This section documents what the evidence shows about non-antibiotic approaches — not to replace the standard of care, but to address three real clinical situations: patients who have experienced treatment failure, patients who cannot tolerate standard regimens, and patients who want adjunctive support alongside antibiotic therapy. The same evidence grading framework applies here as throughout this page: honest, specific, neither dismissive nor overclaiming.
The limitations of standard eradication therapy are now formally documented. Clarithromycin triple therapy fails in 22–31% of cases due to resistance (Ho JJC, et al. Am J Gastroenterol. 2022). Even bismuth quadruple therapy and vonoprazan-based regimens, which represent the current best standard, have intention-to-treat failure rates of 10–15% driven primarily by compliance failure. A demanding regimen of four to five medications twice daily for 14 days with a 20–30% side effect rate produces predictable non-completion in a meaningful fraction of patients.
For patients who have failed one course of treatment and face a second-line regimen with even more demanding compliance requirements, or who have medical reasons that complicate antibiotic use, the question of what else might work is not a fringe inquiry — it is a legitimate clinical need with an underserved evidence base.
Additionally, many of the most commonly used natural compounds in this space have mechanistic rationale for adjunctive use alongside antibiotic therapy — not as replacements, but as agents that address pathways antibiotics do not specifically target: biofilm disruption, urease inhibition, efflux pump inhibition, and physical bacterial removal. Understanding which compounds have evidence for these adjunctive roles is clinically useful regardless of whether antibiotics are part of the treatment plan.
Mastic gum (Pistacia lentiscus resin) is the most studied natural compound for H. pylori and has a reasonably well-characterized mechanism. Mastic gum triterpenic acids — primarily isomasticadienolic acid and oleanolic acid — insert into H. pylori's outer membrane through hydrophobic interactions, disrupting membrane integrity and causing leakage. A second mechanism involves inhibition of H. pylori's 30S ribosomal subunit, impairing protein synthesis through a pathway distinct from standard antibiotic mechanisms. A third pathway blocks H. pylori's BabA-mediated adhesion to Lewis b blood group antigens on the gastric mucosa. Multiple small RCTs demonstrate significant H. pylori bacterial load reduction with mastic gum. None demonstrate monotherapy eradication rates approaching antibiotic regimens. The evidence supports mastic gum as a meaningful adjunct — particularly for patients seeking to reduce bacterial burden alongside or between antibiotic courses — but not as a standalone eradication therapy.
Bismuth compounds are not an alternative — bismuth subcitrate is a standard component of ACG-recommended quadruple eradication therapy. Its mechanisms are directly relevant to this discussion: competitive nickel displacement from urease's active site (collapsing H. pylori's acid shield), outer membrane LPS disruption, and LuxS quorum sensing inhibition that interferes with bacterial community coordination and biofilm formation. The inclusion of bismuth in standard quadruple therapy is one of the reasons that regimen outperforms triple therapy.
Probiotics as adjuncts. The evidence for probiotics in H. pylori management is reasonably well-established in one specific role: reducing antibiotic side effects during eradication therapy. Meta-analytic data supports Lactobacillus rhamnosus GG, Lactobacillus reuteri, and Saccharomyces boulardii for reducing the incidence of diarrhea and improving compliance during antibiotic courses. A specific strain, Lactobacillus reuteri DSM 17648 (commercially available as Pylopass), has a distinct mechanism: co-aggregation — it binds directly to H. pylori cells, forming clumps that are too large to adhere to the gastric mucosa, expelled through normal gastric motility. Multiple human trials across different countries have validated this strain's ability to reduce H. pylori bacterial load. This co-aggregation mechanism is specific to DSM 17648 and does not apply to other L. reuteri strains.
Sulforaphane (from broccoli sprouts) has demonstrated significant anti-H. pylori activity in vitro — including against antibiotic-resistant strains — through broad electrophile activity that makes resistance development mechanistically difficult. Early human data from small studies shows gastric H. pylori burden reduction with concentrated broccoli sprout consumption. Clinical evidence remains insufficient for eradication-level claims; larger trials are needed.
Lactoferrin is an iron-binding glycoprotein whose proposed mechanism against H. pylori involves iron deprivation: H. pylori requires iron for virulence factor production and biofilm formation. Lactoferrin competes with H. pylori for available iron in the gastric environment. Some RCT data shows improved eradication rates when lactoferrin is added to standard triple therapy; effect sizes are modest and the evidence base is not large. Lactoferrin's primary role in a comprehensive adjunctive protocol is likely biofilm disruption support — iron cross-links are structural components of H. pylori biofilm, and lactoferrin's iron-chelating activity can destabilize the biofilm matrix.
Berberine deserves separate treatment because it has the most mechanistically coherent and evidentially supported case for combination use with standard antibiotic therapy among natural compounds in this space. Berberine is an isoquinoline alkaloid found in several plants including barberry (Berberis vulgaris), goldenseal (Hydrastis canadensis), and Oregon grape (Mahonia aquifolium). It has a long history of use in traditional Chinese and Ayurvedic medicine, and a well-characterized modern research profile in metabolic and infectious disease contexts.
The mechanisms against H. pylori are multi-modal and specific:
Biofilm disruption: Berberine disrupts H. pylori biofilm formation at multiple stages — it inhibits the quorum sensing signals that coordinate biofilm initiation, and it degrades established biofilm matrix through interaction with biofilm structural proteins. This mechanism addresses one of the primary reasons H. pylori is difficult to eradicate: the biofilm that reduces antibiotic penetration by orders of magnitude at the site of infection.
Urease inhibition: Berberine inhibits H. pylori urease activity — the enzyme responsible for creating the acid-neutralizing ammonia shield that protects the bacterium from gastric acid. Without the urease shield, H. pylori becomes more vulnerable to both acid and antimicrobial agents. This mechanism is additive with bismuth's urease inhibition through competitive nickel displacement — two compounds inhibiting the same target through different mechanisms.
Direct bacteriostatic and bactericidal effects: Berberine has documented direct activity against H. pylori in vitro, including activity against clarithromycin-resistant strains, through intercalation into bacterial DNA, inhibition of topoisomerase enzymes, and membrane disruption at higher concentrations.
Anti-inflammatory effects: Berberine inhibits NF-κB activation in gastric epithelial cells — the same inflammatory pathway that CagA activates — reducing the cytokine burden independently of direct bacterial killing.
The combination evidence: Published studies examining berberine combined with standard antibiotic triple or quadruple therapy demonstrate improved eradication rates compared to antibiotic therapy alone. The mechanistic rationale for these improvements is coherent: berberine disrupts biofilm and urease (increasing antibiotic access and reducing the acid shield protecting the bacteria), while antibiotics target bacterial replication through DNA and cell wall mechanisms. The mechanisms are additive rather than redundant. Evidence grade: Moderate. The combination data is promising and mechanistically well-grounded; the studies are mostly small and require replication in larger trials before berberine-combination therapy can be characterized as established practice.
One practical note: not all berberine products are equivalent. For H. pylori-specific use, whole-plant alkaloid extracts from Coptis chinensis (Chinese goldthread) are particularly relevant because they contain berberine alongside coptisine and palmatine — three alkaloids that work through partially distinct but complementary mechanisms, providing broader coverage than isolated berberine alone.
The structural funding problem. Large randomized controlled trials are expensive — typically millions of dollars for an adequately powered study. The funding model for large clinical trials is almost entirely pharmaceutical: companies fund trials for compounds they can patent and profit from. Natural compounds — mastic gum, berberine, sulforaphane, lactoferrin — are unpatentable. No pharmaceutical company will fund large RCTs for unpatentable compounds. The result is a landscape where the compounds with the most commercial potential receive the most rigorous investigation, and compounds with genuine biological activity but no patent potential receive small, heterogeneous studies that cannot definitively establish or refute their clinical utility. Absence of strong evidence is not the same as evidence of absence. This is especially true for compounds with coherent mechanisms and consistent in vitro and early human signals.
Publication bias. Positive findings in small studies are more likely to be published than negative findings in small studies. This creates an overrepresentation of positive signals in the literature for any compound with active research interest. The true effect sizes may be smaller than the published literature suggests. Welyon's three-tier evidence rubric is designed to account for this: compounds with small-study positive signals and no large-trial replication are classified as Moderate or Exploratory, not Strong.
Vaccine development. Multiple H. pylori vaccine candidates have been in various stages of clinical trial over the past two decades. No vaccine has successfully completed the transition from animal models to an approved human product, though research programs remain active. A preventive vaccine would be the most significant advance in H. pylori management since the discovery of eradication therapy — preventing acquisition rather than treating it. The development pipeline remains active and bears watching.
Given the evidence gap, the compliance and resistance limitations of standard therapy, and the real-world patient interest in adjunctive and alternative approaches, Welyon is developing a structured observational data collection program.
What it is: A pre-registered, IRB-approved prospective observational cohort study tracking patient-reported outcomes and biomarker data across different H. pylori eradication approaches — antibiotic-based, adjunctive, and alternative — in willing participants. Participants choose their own eradication approach; Welyon collects, organizes, and publishes outcomes transparently. The primary endpoint is confirmed eradication, verified by C13 urea breath test at 4–6 weeks post-protocol. Secondary endpoints include iron saturation, ferritin, serum B12, and validated symptom scales including the Leeds Dyspepsia Questionnaire, GSRS, Chalder Fatigue Scale, and UAS7. Exploratory endpoints include TPO antibodies, PHQ-9, and GAD-7. Target enrollment: 500+ participants for first manuscript submission.
What it is not: This is not a clinical trial. It does not randomize treatment or produce RCT-level evidence. It is an organized attempt to build real-world observational data where controlled trial evidence does not yet exist — the kind of evidence that has historically motivated larger controlled studies when it shows consistent signals across a meaningful patient cohort.
Why this matters: Standard H. pylori care does not systematically collect before-and-after data on the systemic health consequences of eradication. A patient who eradicates H. pylori and then sees their iron levels recover over six months produces no data — their outcome exists only in their own medical records, fragmented across multiple specialists. Welyon's observational program aggregates these outcomes systematically, creates a documented evidence base for the downstream condition improvements post-eradication, and in doing so produces information the field currently lacks regardless of what eradication approach participants use.
The observational study is in development. If you are interested in participating or following its progress:
Join the waitlist →This section documents recent developments in H. pylori research. Entries are added as significant research emerges and presented in reverse chronological order. The page's dateModified schema tag is updated with each addition.
A 2024 bidirectional Mendelian randomization study in Science Advances used genetic variants associated with H. pylori outer membrane protein antibody levels as natural instruments to test causal direction between H. pylori infection and thyroid autoimmunity. The study found that genetically elevated H. pylori OMP antibody levels are associated with increased risk of hyperthyroidism and Graves' disease — providing genetic causal evidence that goes beyond observational association. Mendelian randomization addresses confounding in ways that standard observational studies cannot, and this methodology is considered among the strongest available evidence for causation in human populations short of a randomized trial. The finding strengthens the thyroid autoimmunity association from consistent observation to genetic causal support.
Wang K, et al. Sci Adv. 2024;10(31):eadi8646.
The 2024 American College of Gastroenterology Clinical Guideline on H. pylori treatment formally deprecated clarithromycin triple therapy (PPI + clarithromycin + amoxicillin) as first-line treatment in areas of high clarithromycin resistance. Clarithromycin resistance rates in the US have reached 22–31%, making this regimen — the most commonly prescribed H. pylori treatment in the US — unreliable in approximately one in four patients. The guideline simultaneously introduced vonoprazan-based regimens as recommended alternatives: vonoprazan-amoxicillin dual therapy and vonoprazan-based triple therapy achieved eradication in roughly 80–85% of patients overall, outperforming standard PPI triple therapy — including in clarithromycin-resistant infections. Despite the guideline change, more than half of US H. pylori patients continue to receive the deprecated clarithromycin-based regimen — the practice-guideline gap persists.
Chey WD, et al. Am J Gastroenterol. 2024. · Ho JJC, et al. Am J Gastroenterol. 2022;117(8):1221–1230. · Chey WD, et al. Gastroenterology. 2022;163(3):608–619.
A 2022 systematic review formally recommended H. pylori testing as part of the differential evaluation for unexplained iron deficiency anemia — elevating the iron–H. pylori connection from a research finding to a clinical recommendation. This is the first formal endorsement of H. pylori testing as part of the IDA differential workup in a systematic review context, and it joins the existing randomized-trial evidence that adding eradication to iron improves iron stores. The recommendation is not yet consistently reflected in standard hematology or primary care practice, where H. pylori testing in iron deficiency remains uncommon in the absence of GI symptoms.
Hudak L, et al. Helicobacter. 2017;22(1):e12330 (meta-analysis; 7 RCTs for the intervention outcome).
What is H. pylori?
Helicobacter pylori is a gram-negative bacterium that colonizes the lining of the stomach. It is carried by approximately one in three Americans and up to 44% of the global population — and considerably higher in parts of Asia, Africa, and Latin America where prevalence can exceed 70%. The World Health Organization classifies H. pylori as a Group 1 carcinogen — the highest classification — due to its documented role in causing gastric cancer. It is the best-established bacterial carcinogen in humans and the only bacterium currently classified by the WHO as a Group 1 carcinogen. Most people who carry it experience no obvious gastrointestinal symptoms and are unaware they are infected. Without treatment, H. pylori persists for life — the human immune system does not spontaneously clear it.
Can H. pylori cause iron deficiency?
Yes — and this is one of the strongest documented associations in the H. pylori extra-gastric evidence base. People with H. pylori are roughly 1.7 times more likely to have iron-deficiency anemia, and randomized trials show that adding H. pylori eradication to iron supplementation raises iron stores (ferritin) more reliably than iron supplementation alone in adults with unexplained iron deficiency — though the hemoglobin benefit is less consistent across trials. The bacterium interferes with iron absorption through two documented mechanisms: mislocalisation of the transferrin receptor (redirecting iron toward the bacterium rather than systemic absorption) and depletion of gastric ascorbic acid by an estimated 50–80% (impairing the Fe3+→Fe2+ conversion required for non-heme iron absorption). Testing for H. pylori is increasingly recommended as part of the evaluation for unexplained iron deficiency anemia.
Why won't my iron levels improve with supplements?
Refractory iron deficiency — iron levels that do not respond to supplementation, or that return to deficient levels after supplementation stops — is the clinical signature of an active depletion mechanism that supplementation cannot overcome. If H. pylori is present and actively disrupting iron absorption through the transferrin receptor and ascorbic acid mechanisms, supplementation adds iron to a system that is continuously depleting it. The deficiency returns because the cause remains active. Randomized trials show that adding eradication to iron supplementation raises iron stores more reliably than iron alone in adults with unexplained or supplement-resistant iron deficiency — with improvement in iron markers typically seen over 6–12 months in patients who achieve confirmed clearance.
Can H. pylori cause fatigue?
H. pylori is associated with fatigue through multiple overlapping mechanisms: chronic systemic cytokine burden (TNF-alpha, IL-6) impairing cellular energy metabolism and HPA axis regulation; iron deficiency reducing oxygen-carrying capacity; B12 deficiency impairing mitochondrial energy production; and gut-brain axis disruption affecting sleep quality and neurological function. Small studies using validated fatigue instruments such as the Chalder Fatigue Scale report improvement in fatigue scores following successful eradication in H. pylori-positive patients, with the largest benefit in those who also had iron or B12 deficiency. The evidence is classified as Moderate — the association is consistent, the mechanistic pathways are documented, and the eradication outcome data supports the connection — but the studies are smaller and more heterogeneous than in the iron and ITP categories.
Can H. pylori cause thyroid problems?
H. pylori is associated with thyroid autoimmunity — including Hashimoto's thyroiditis and Graves' disease — in the peer-reviewed literature. A meta-analysis of 15 studies found H. pylori infection roughly twice as common in people with autoimmune thyroid disease as in controls. The proposed mechanism is molecular mimicry: H. pylori's CagA surface proteins share structural features with thyroid peroxidase and thyroglobulin, and antibodies generated against the infection cross-react with thyroid tissue. Multiple studies document reduction in thyroid (TPO) antibody levels following eradication. A 2024 Mendelian randomization study in Science Advances found genetic evidence for a causal link specifically with Graves' disease and hyperthyroidism. The evidence is classified as Moderate — the association is consistent and the causal case is strengthening, but eradication does not improve thyroid autoimmunity in all patients. H. pylori does not appear in any endocrinology guideline for Hashimoto's or Graves' disease.
Can H. pylori cause skin problems or chronic hives?
Pooled analyses of randomized trials (361 patients) find that H. pylori-positive people with chronic spontaneous urticaria (CSU) are more likely to go into remission after eradication therapy than those who are not treated — though estimates vary and one meta-analysis found the benefit may not depend on whether the bacterium is fully cleared. The proposed mechanism involves molecular mimicry: anti-CagA antibodies cross-react with skin mast cell surface antigens, triggering mast cell degranulation and histamine release. A separate analysis of 22 studies and 1,385 patients found higher spontaneous remission in H. pylori-negative CSU patients compared to positive patients — consistent with the infection maintaining the condition in a subset of carriers. H. pylori testing is not standard in dermatology or allergy workup for chronic hives.
Can H. pylori cause brain fog?
H. pylori is associated with cognitive symptoms — difficulty concentrating, reduced processing speed, word retrieval difficulty — through four documented mechanisms: systemic cytokines (TNF-alpha, IL-6) crossing the blood-brain barrier and triggering neuroinflammation; B12 deficiency impairing neurological function and myelination; VacA molecular mimicry with neural tissue antigens; and enteric neurotransmitter disruption through the gut-brain axis. Small studies using validated cognitive instruments report cognitive improvement following eradication in H. pylori-positive patients. The evidence is classified as Moderate — the mechanistic case is strong; the interventional studies are smaller and less standardized than in the iron and ITP categories.
Does H. pylori go away on its own?
No. The human immune system does not spontaneously clear H. pylori. The bacterium has evolved specific mechanisms to evade immune clearance — including modulation of the local immune response to suppress rather than eliminate the infection, urease-based acid protection, biofilm formation, and the ability to enter a dormant coccoid state when threatened. Most evidence suggests infection persists throughout adulthood in virtually all untreated cases — spontaneous clearance has not been demonstrated at any meaningful rate in the peer-reviewed literature. Without a specific course of treatment designed to eliminate it, H. pylori persists in the vast majority of carriers.
How do you test for H. pylori?
The two recommended non-invasive options for detecting active H. pylori infection are the monoclonal stool antigen test (sensitivity and specificity 90–94%) and the urea breath test (sensitivity and specificity 95–96%). Both detect active infection. The blood antibody (serology) test detects antibodies but cannot distinguish active infection from past infection — it is not recommended for initial diagnosis by current ACG guidelines and is inappropriate for post-treatment confirmation. Accurate testing requires medication washout: PPIs should be stopped at least 14 days before testing, antibiotics at least 28 days, and bismuth-containing compounds at least 14 days. Failing to observe these washout periods is the most common cause of false-negative results in practice. H2 blockers do not require washout.
What happens after H. pylori eradication?
Outcomes following eradication depend on the condition, the infection duration, and the individual. In iron deficiency, improvement in iron stores is documented over 6–12 months in patients who achieve confirmed clearance. In ITP, platelet counts recover in roughly half of H. pylori-positive patients. In chronic spontaneous urticaria, eradication is associated with higher remission rates. In B12 deficiency, measurable improvement in active B12 markers at 6–12 months. Eradication does not guarantee resolution — the contribution of H. pylori varies by patient, infection duration, strain virulence, and condition severity. Systemic improvements typically appear over months following eradication, not within days of completing treatment. Confirmatory post-treatment testing — urea breath test or stool antigen, at least 4 weeks after completing the antibiotic course — is recommended to verify eradication, as treatment failure rates are real.
What conditions are associated with H. pylori beyond the stomach?
The peer-reviewed literature documents associations between H. pylori and eight systemic conditions: iron deficiency anemia, immune thrombocytopenic purpura (ITP), chronic spontaneous urticaria, thyroid autoimmunity (Hashimoto's thyroiditis and Graves' disease), unexplained fatigue, vitamin B12 deficiency and associated nerve symptoms, brain fog and cognitive impairment, and metabolic syndrome. Evidence strength varies by condition. Iron deficiency and ITP carry strong interventional evidence from multiple randomized controlled trials. Chronic urticaria, thyroid autoimmunity, B12 deficiency, fatigue, and brain fog carry moderate evidence from consistent cohort studies and smaller interventional trials — urticaria the best-supported, with nine RCTs. Metabolic syndrome is graded exploratory — the association is consistent but its causal direction is not established. None of these conditions include H. pylori testing in their standard diagnostic algorithms in most specialties.
How common is H. pylori in the United States?
Approximately one in three Americans carries H. pylori — a figure derived from NHANES data and regional studies, though the exact current prevalence is uncertain in the 25–35% range. The commonly cited 30–40% figure reflects older data that may overstate current active infection rates, partly because antibody tests (which can remain positive after successful eradication) have historically been used in prevalence studies. The cohort effect is also relevant: Americans born in more recent decades had lower childhood H. pylori acquisition rates than prior generations, so as older cohorts age out, overall prevalence is declining. Prevalence is not uniform — higher rates occur in lower-income households, crowded living conditions, and populations with immigration from higher-prevalence regions where H. pylori rates can exceed 70%.
Does H. pylori strain matter?
Yes, significantly. H. pylori is not one thing — hundreds of strains have been sequenced with meaningful differences in virulence. The most clinically significant distinction is CagA status. CagA-positive strains inject the CagA protein directly into gastric epithelial cells via a type IV secretion system, triggering more intense inflammation, higher cancer risk, and more vigorous molecular mimicry-driven autoimmune effects — including the downstream systemic conditions documented in Section III. CagA-negative strains are generally less inflammatory and carry lower downstream risk. Standard stool antigen and breath tests detect H. pylori presence but do not identify strain type. Strain-specific testing — available through advanced molecular assays — provides CagA status alongside the positive/negative result and changes the risk context of a positive result meaningfully, though it does not currently change the antibiotic treatment protocol.
Why don't doctors test for H. pylori more often?
The barrier is structural rather than scientific. Medicine is organized by organ system and specialty — gastroenterologists manage stomach conditions, hematologists manage blood disorders, endocrinologists manage thyroid conditions. H. pylori testing is embedded in gastroenterology workflows for patients with GI symptoms, but it is not embedded in the diagnostic frameworks of the specialists who manage the downstream conditions associated with H. pylori. Even where guidelines support testing ITP patients for H. pylori, real-world testing is low — in an international survey of 186 hematologists across 39 countries, only 29% said they always test ITP patients for H. pylori (Vishnu P, et al. J Thromb Haemost. 2021). The gap is one of education and workflow, not of evidence.
Can I test for H. pylori if I'm on a PPI?
Yes — with an important caveat about how to interpret the result. PPIs suppress H. pylori metabolic activity, which reduces antigen shedding (detectable by the stool antigen test) and urease production (detectable by the breath test). This means PPIs can cause false-negative results. However, PPIs cannot cause false positives — they can only make a real infection harder to detect, not create the appearance of an infection that isn't there. If you test positive while on a PPI, that result is reliable — the suppression was insufficient to hide the infection. If you test negative while on a PPI, that result is ambiguous — it may be a true negative or a suppressed positive that needs to be repeated after a 14-day PPI washout to distinguish.
What is the most accurate H. pylori test?
For detecting active infection, the urea breath test is the most accurate non-invasive option, with sensitivity and specificity of 95–96%. It directly measures H. pylori's urease enzyme activity in exhaled breath and is considered the gold standard for non-invasive active-infection testing. The monoclonal stool antigen test is also highly accurate (90–94% sensitivity and specificity) and is the first-line recommended test by 2024 ACG guidelines. A newer option — PCR-based molecular stool testing — matches the accuracy of the urea breath test and additionally identifies clarithromycin resistance mutations, making it the most informative single test available. Serology (blood antibody test) is the least appropriate for assessing current infection status: it cannot distinguish active from past infection and is not recommended for initial diagnosis.
What are the risks of H. pylori eradication treatment?
H. pylori eradication therapy carries real but finite risks. Antibiotic courses commonly produce nausea, diarrhea, metallic taste (particularly from metronidazole), and abdominal discomfort during the 14-day treatment period. Gut dysbiosis — disruption of the gut microbiome — can persist for months after completing treatment; probiotics added to the regimen reduce but do not eliminate this effect. C. difficile risk exists but is low with standard eradication regimens. Patients with penicillin allergy require regimens that avoid amoxicillin. PPIs used as part of eradication therapy are generally well-tolerated in the short term — the risks associated with PPI use are more relevant to long-term maintenance use than to a 14-day treatment course. The risks of leaving H. pylori untreated — progressive gastric damage following Correa's Cascade, ongoing systemic downstream effects, indefinite dependence on symptomatic management — generally outweigh the finite risks of a 14-day treatment course for most patients.
Can H. pylori affect stomach acid levels?
Yes — and in opposite directions depending on where in the stomach the infection is primarily located. When H. pylori colonizes predominantly in the antrum (the lower stomach), it stimulates gastrin release and drives acid hypersecretion — excess acid that contributes to duodenal ulcer formation and classic reflux symptoms. When H. pylori colonizes predominantly in the corpus (the body of the stomach) and causes progressive atrophic gastritis, it destroys parietal cells over time and produces hypochlorhydria — reduced acid output. The hypochlorhydric state impairs iron absorption, B12 absorption, and allows bacterial overgrowth in the upper GI tract. Patients with corpus-predominant H. pylori often have minimal GI symptoms despite significant downstream consequences — because the low-acid state reduces pain while worsening nutritional absorption.
Can H. pylori cause low ferritin?
Yes — low ferritin (the iron storage protein) is one of the most documented extra-gastric consequences of H. pylori infection. H. pylori interferes with iron absorption through two mechanisms: mislocalisation of the transferrin receptor, which redirects iron toward the bacterium rather than systemic absorption, and depletion of ascorbic acid in the gastric lumen by an estimated 50–80%, impairing the conversion of dietary iron to its absorbable form. The result is depleted iron stores that do not respond to supplementation while the infection remains active. Randomized trials show that adding H. pylori eradication to iron supplementation raises iron stores (ferritin) more reliably than supplementation alone.
Can H. pylori cause B12 deficiency?
Yes. H. pylori causes progressive inflammation of the gastric corpus — the part of the stomach where parietal cells reside. Parietal cells produce intrinsic factor, the protein required for B12 absorption in the small intestine. As H. pylori damages parietal cells over time through both inflammatory and autoimmune mechanisms, intrinsic factor production falls and B12 absorption fails regardless of dietary intake. Studies show measurable improvement in active B12 markers (methylmalonic acid and holotranscobalamin) over 6–12 months following successful eradication in B12-deficient patients. B12 supplementation treats the deficiency but does not address the absorption problem while the infection remains active.
Can H. pylori cause anxiety or depression?
H. pylori is associated with anxiety and mood symptoms through the gut-brain axis — specifically through systemic cytokines (TNF-alpha, IL-6) crossing the blood-brain barrier and triggering neuroinflammation, and through disruption of enteric neurotransmitter production including serotonin precursors. The enteric nervous system produces approximately 90% of the body's serotonin. Studies using validated instruments including PHQ-9 and GAD-7 document mood and anxiety improvement following eradication in H. pylori-positive patients. The evidence is classified as Moderate — the mechanistic pathways are documented but the interventional evidence for mood specifically is less robust than for iron deficiency or ITP.
Can H. pylori cause weight loss?
H. pylori infection is associated with unintentional weight loss through several mechanisms: reduced appetite from inflammation-driven anorexia, disrupted ghrelin signaling (H. pylori reduces ghrelin-producing cell density in the gastric fundus, altering appetite regulation), and nutrient malabsorption from impaired iron and B12 absorption. Weight loss is more commonly associated with active symptomatic H. pylori infection, particularly when gastric inflammation is significant. Some studies document modest weight gain following eradication as appetite and nutrient absorption normalize.
Can H. pylori cause reflux or GERD?
The relationship between H. pylori and reflux is complex and goes in both directions depending on where in the stomach the infection is located. Antrum-predominant H. pylori stimulates excess acid production, which can contribute to or worsen reflux symptoms. Paradoxically, corpus-predominant H. pylori with atrophic gastritis reduces acid production — and some evidence suggests this lower-acid state may actually protect against esophageal reflux and esophageal adenocarcinoma. The relationship between H. pylori eradication and reflux is therefore not straightforward: eradication sometimes improves reflux (in antrum-predominant patients) and sometimes has no effect or may temporarily worsen it (in corpus-predominant patients as acid normalizes).
Can H. pylori cause autoimmune disease?
H. pylori is associated with several autoimmune conditions through a mechanism called molecular mimicry — H. pylori surface proteins share structural features with human tissue antigens, and antibodies generated against the infection cross-react with the body's own tissues. Documented associations include immune thrombocytopenic purpura (ITP), Hashimoto's thyroiditis, Graves' disease, and chronic spontaneous urticaria. Evidence strength varies: ITP has the strongest evidence including guideline endorsement from the American Society of Hematology; thyroid autoimmunity has a 2024 Mendelian randomization study supporting genetic causal direction; urticaria has nine RCTs. H. pylori does not cause all autoimmune disease, and not every H. pylori-positive person develops autoimmune complications — host genetic susceptibility also plays a role.
Can H. pylori cause dizziness or heart palpitations?
Dizziness and palpitations are not primary documented associations of H. pylori in the peer-reviewed literature, but both can occur as downstream consequences of H. pylori-associated conditions. Severe iron deficiency anemia — which H. pylori can cause through malabsorption mechanisms — produces dizziness, lightheadedness, and palpitations from reduced oxygen-carrying capacity. B12 deficiency from H. pylori-associated intrinsic factor impairment can produce neurological symptoms including dizziness. If dizziness or palpitations co-occur with refractory iron deficiency or unexplained B12 deficiency, H. pylori investigation is warranted as part of the upstream workup for those conditions.
What is the difference between H. pylori testing and H. pylori treatment?
Testing determines whether H. pylori is present. Treatment — eradication therapy — eliminates it. They are separate steps. Standard testing uses either the monoclonal stool antigen test (sensitivity/specificity 90–94%) or the urea breath test (95–96%) to detect active infection. Treatment uses antibiotic combination regimens — currently bismuth quadruple therapy or vonoprazan-based regimens as first-line per 2024 ACG guidelines — for 14 days. A critical third step that is frequently skipped in clinical practice is confirmatory testing: retesting 4 or more weeks after completing treatment to verify eradication was successful. Treatment failure rates of 10–30% mean a meaningful fraction of patients who complete a course remain infected without knowing it.
This section is for readers who want the complete picture — the methodological limitations, the unresolved questions, and the associations that don't fit neatly into the main evidence framework. It does not contradict the evidence presented in Sections II and III. It completes it.
The causality framework introduced in Section II (§ 2.7) merits extension here for readers who want the full picture. The evidence in Section III spans a wide range of causal strength. For iron deficiency and ITP, the RCT evidence is strong enough that the causal question is largely settled in clinical practice — eradication resolves the condition in a meaningful fraction of positive patients, and the mechanism is characterized well enough that the relationship is considered established. For thyroid autoimmunity, a 2024 Mendelian randomization study (Wang K, et al. Sci Adv. 2024;10(31):eadi8646) has moved the evidence toward a causal direction specifically for Graves' disease and hyperthyroidism. For urticaria, the pooled randomized-trial evidence is consistent across the nine trials, though the confidence intervals are wide and the benefit may not depend on successful eradication.
For metabolic syndrome, fatigue, and brain fog, the evidence is primarily observational, supplemented by smaller interventional studies. The causal question for these conditions is not settled — the associations are real and consistent, the mechanisms are plausible, but alternative explanations (reverse causation, confounding) cannot be excluded on current evidence.
The honest summary: Welyon does not claim that H. pylori causes all eight conditions in all positive patients. The claim is that H. pylori is a documented upstream contributor in a meaningful subset, that this subset is not being identified because the testing is not being done, and that investigating H. pylori is warranted given the available evidence and the low cost and risk of the test. That is a defensible, honest, evidence-grounded position — not a stronger claim than the evidence supports.
The relationship between H. pylori prevalence and H. pylori disease burden is not linear. A national prevalence estimate of 30% does not mean 30% of Americans are experiencing H. pylori-driven harm. Downstream disease burden is concentrated in the fraction of that 30% carrying CagA-positive, VacA s1/m1, BabA-positive strains — the most virulent strain combinations. The fraction carrying CagA-negative strains with low-virulence VacA alleles may experience little or no systemic downstream harm from the infection.
This heterogeneity has several implications for interpreting association studies. First, studies that do not stratify by CagA status may underestimate the effect size in the CagA-positive subgroup by diluting it with the CagA-negative subgroup where the mechanism is weaker or absent. Second, population-level prevalence studies and disease burden estimates are measuring different things — and conflating them can produce both overestimates (assuming all 30% are at equal risk) and underestimates (assuming the association doesn't exist because the effect is diluted in unstratified samples).
H. pylori's effects on gastric acid — described in the gastric acid paradox section — create a methodological challenge for association research that extends beyond the direct virulence mechanisms. In corpus-predominant patients with hypochlorhydria, the low-acid gastric environment has downstream consequences independent of H. pylori's direct virulence effects: impaired iron and B12 absorption through acid-dependent mechanisms, altered upper GI microbiome composition (low acid allows bacterial overgrowth that wouldn't occur in a normal gastric environment), and magnesium malabsorption.
When researchers studying H. pylori associations observe iron deficiency, B12 deficiency, or gut-related symptoms in H. pylori-positive patients, they face a genuine methodological challenge: is this driven by direct bacterial virulence (CagA/VacA mechanisms), by indirect acid-physiology effects (hypochlorhydria), or by both simultaneously? Most observational studies cannot disentangle these. Even RCT evidence — which establishes that eradication helps — does not distinguish whether the benefit came from removing the direct virulence mechanisms or from restoring gastric acidity or both. This does not undermine the clinical value of eradication — the outcome is the same regardless of which mechanism dominates. But it is relevant to understanding the precise biological pathway and to designing future studies that can answer more specific mechanistic questions.
Decades of research interest in H. pylori's associations have produced a long list of reported connections. Some are well-established. Some are weak. Some may not survive replication in larger and better-controlled studies. The published literature on H. pylori associations is subject to publication bias: positive findings are more likely to be published than null findings, particularly in smaller studies. This means the literature systematically overrepresents positive associations and underrepresents negative findings. For any association where the evidence base consists primarily of small studies with positive results, the true effect size is likely smaller than the published literature suggests.
Welyon's three-tier evidence rubric is explicitly designed to account for this. Strong classification requires replicated meta-analytic or RCT evidence — a standard that is not met by a single positive small study regardless of how striking the result. Moderate requires consistent evidence across multiple studies with some interventional support — not a single positive finding. Exploratory acknowledges early mechanistic or observational signals that require replication before clinical conclusions can be drawn. The eight conditions in Section III were selected because they meet the Moderate or Strong threshold on this rubric — not because every published association with H. pylori was included. Many published associations are noted in this section because the evidence does not yet meet the threshold for the Moderate classification.
A strand of research deserves acknowledgment that runs counter to the narrative of H. pylori as purely harmful: the possibility that H. pylori plays a role in normal gastric physiology, and that its eradication may have unintended consequences. Several observational studies have documented inverse associations between H. pylori infection and conditions including asthma, allergies, inflammatory bowel disease (including Crohn's disease), esophageal adenocarcinoma, and gastroesophageal reflux disease. The proposed mechanism is the hygiene hypothesis framework: H. pylori, as a long-term human commensal that has co-evolved with our species for 100,000 years, may play a role in calibrating the immune system during early development.
Some research also suggests that non-pathogenic H. pylori strains may beneficially normalize stomach acid secretion and regulate appetite through ghrelin. These findings are real and deserve acknowledgment. They do not change the risk-benefit calculation for eradication in H. pylori-positive patients with documented infection and potential downstream effects — the evidence for harm from persistent infection in those patients outweighs the hypothetical protective effects. But they illustrate that our understanding of H. pylori's relationship with human physiology is incomplete, and that the framing of H. pylori as purely pathogenic may be an oversimplification. This is an active area of investigation that this page will update as the evidence develops.
Multiple observational studies document associations between H. pylori infection and ischemic heart disease and stroke. The proposed mechanisms are consistent with the systemic pathways described in Section II: endothelial inflammation from the chronic cytokine burden, platelet activation through molecular mimicry pathways, and altered lipid metabolism. The association is epidemiologically consistent across multiple studies. The causal direction is not established. The evidence does not meet Welyon's Moderate classification threshold for inclusion in the eight downstream conditions — the interventional evidence (demonstrating that eradication reduces cardiovascular events) does not yet exist at the scale needed. The cardiovascular associations are noted here as an emerging area of investigation that may produce stronger evidence as prospective studies with cardiovascular endpoints are conducted.
A modest association between H. pylori infection and colorectal polyp formation and colorectal cancer has been documented across multiple studies. Larger adenomatous polyps are more commonly found in H. pylori-positive patients in some analyses. The proposed mechanisms involve systemic inflammation (the same cytokine burden that may affect multiple organ systems) and possible direct effects via gastrin — which H. pylori stimulates in antrum-predominant colonization and which has proliferative effects on colorectal mucosa. Causality has not been established. This association does not meet the Moderate threshold at this time. It is included here because it is an active area of investigation and because a colorectal cancer connection would be clinically significant if established.
FDA disclaimer. These statements have not been evaluated by the Food and Drug Administration. This page is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before acting on any information published here.
Commercial interest disclosure. Welyon publishes this reference as part of its educational mission and sells H. pylori investigation guides, a test kit, and is developing a supplement protocol and physician-supervised eradication program. Evidence grading follows a single rubric applied identically regardless of which conditions or products are most commercially relevant to Welyon. No claims are softened or strengthened for commercial benefit.
References are ordered by first appearance in the text. Where a source is cited in multiple sections, it appears once below at its first citation point. All references were verified as of June 2026.
Each citation is tagged with the evidence tier shown below, along with the nature or highlights of the study.